<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11788153</article-id><article-id pub-id-type="pmcid-ver">PMC11788153.1</article-id><article-id pub-id-type="pmcaid">11788153</article-id><article-id pub-id-type="pmcaiid">11788153</article-id><article-id pub-id-type="pmid">39902052</article-id><article-id pub-id-type="doi">10.3389/fimmu.2024.1501791</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>
<italic toggle="yes">Brucella suis</italic> &#916;<italic toggle="yes">mapB</italic> outer membrane vesicles as an acellular vaccine against systemic and mucosal <italic toggle="yes">B. suis</italic> infection</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Gonz&#225;lez</surname><given-names initials="FM">Florencia Mu&#241;oz</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/632819"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name name-style="western"><surname>Bialer</surname><given-names initials="MG">Magali G.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="fn003" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/240192"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Cerutti</surname><given-names initials="ML">Maria L.</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/2853011"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Estein</surname><given-names initials="SM">Silvia M.</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/236920"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ramis</surname><given-names initials="LY">Lila Y.</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Baldi</surname><given-names initials="PC">Pablo C.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/404135"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Zorreguieta</surname><given-names initials="&#xC1;">&#193;ngeles</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#8225;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/139903"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name name-style="western"><surname>Ferrero</surname><given-names initials="MC">Mariana C.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><xref rid="fn004" ref-type="author-notes">
<sup>&#8225;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/468298"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Facultad de Farmacia y Bioqu&#237;mica, C&#225;tedra de Inmunolog&#237;a, Universidad de Buenos Aires</institution>, <addr-line>Buenos Aires</addr-line>, <country>Argentina</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Instituto de Estudios de la Inmunidad Humoral (IDEHU), CONICET-Universidad de Buenos Aires</institution>, <addr-line>Buenos Aires</addr-line>, <country>Argentina</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Fundaci&#243;n Instituto Leloir (FIL), IIBBA-CONICET (CONICET-FIL)</institution>, <addr-line>Buenos Aires</addr-line>, <country>Argentina</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Centro de Redise&#241;o e Ingenier&#237;a de prote&#237;nas (CRIP), Universidad Nacional de San Mart&#237;n</institution>, <addr-line>Buenos Aires</addr-line>, <country>Argentina</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Laboratorio de Inmunolog&#237;a, Departamento de Sanidad Animal y Medicina Preventiva (SAMP), Centro de Investigaci&#243;n Veterinaria Tandil (CIVETAN-CONICET-CICPBA), Facultad de Ciencias Veterinarias (FCV), Universidad Nacional del Centro de la Provincia de Buenos Aires (UNCPBA)</institution>, <addr-line>Tandil, Buenos Aires</addr-line>, <country>Argentina</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>Departamento de Qu&#237;mica Biol&#243;gica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires</institution>, <addr-line>Buenos Aires</addr-line>, <country>Argentina</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Srinivasa Reddy Bonam, Indian Institute of Chemical Technology (CSIR), India</p></fn><fn fn-type="edited-by"><p>Reviewed by: Mauricio C&#233;sar De Marzi, National University of Luj&#225;n, Argentina</p><p>Amit K. Singh, Albany Medical College, United States</p></fn><corresp id="fn001">*Correspondence: &#193;ngeles Zorreguieta, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:azorreguieta@leloir.org.ar">azorreguieta@leloir.org.ar</email>; Mariana C. Ferrero, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:ferrerom@ffyb.uba.ar">ferrerom@ffyb.uba.ar</email></corresp><fn fn-type="equal" id="fn003"><p>&#8224;These authors have contributed equally to this work and share first authorship</p></fn><fn fn-type="equal" id="fn004"><p>&#8225;These authors have contributed equally to this work and share last authorship</p></fn></author-notes><pub-date pub-type="epub"><day>20</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">454094</issue-id><elocation-id>1501791</elocation-id><history><date date-type="received"><day>25</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>03</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-25 00:25:15.813"><day>25</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 Gonz&#225;lez, Bialer, Cerutti, Estein, Ramis, Baldi, Zorreguieta and Ferrero</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Gonz&#225;lez, Bialer, Cerutti, Estein, Ramis, Baldi, Zorreguieta and Ferrero</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-15-1501791.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="correction-forward" xml:lang="en" xlink:title="correction" vol="16" journal-id="Front Immunol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11841376"><article-title>Corrigendum: <italic>Brucella suis</italic> &#916;<italic>mapB</italic> outer membrane vesicles as an acellular vaccine against systemic and mucosal <italic>B. suis</italic> infection</article-title><volume>16</volume><date><day>5</day><month>2</month><year>2025</year></date><elocation-id>1565688</elocation-id><source>Frontiers in Immunology</source><pub-id pub-id-type="doi">10.3389/fimmu.2025.1565688</pub-id><pub-id pub-id-type="pmcid">PMC11841376</pub-id><pub-id pub-id-type="pmid">39981251</pub-id></related-article><abstract><sec><title>Introduction</title><p>Swine brucellosis, caused by <italic toggle="yes">Brucella suis</italic>, is a worldwide infectious zoonotic disease. Currently, there are no available human or porcine vaccines to protect against <italic toggle="yes">B. suis</italic> infection, which is primarily acquired through the mucosa. We recently described <italic toggle="yes">B. suis</italic> MapB, the homologous protein of TamB, the inner membrane component of the TAM system. Our findings indicate that MapB is involved in bacterial cell envelope homeostasis. In this study, we characterize the outer membrane vesicles (OMVs) of <italic toggle="yes">B. suis</italic> 1330 (wt) and those of <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> (&#916;<italic toggle="yes">mapB</italic>) mutant strain and evaluate their vaccine potential in mice.</p></sec><sec><title>Methods</title><p>OMVs were isolated using the ultracentrifugation method and characterized through electron microscopy, Dynamic Light Scattering, SDS-PAGE and proteomics. Immunogenicity was assessed by intramuscular immunization of mice with wt OMVs or &#916;<italic toggle="yes">mapB</italic> OMVs, followed by the measurement of antigen-specific antibody levels and functional assays to evaluate the protective capacity of the antibodies. Cellular immunity was assessed by characterizing cytokine secretion through ELISA after <italic toggle="yes">in vitro</italic> stimulation of spleen cells with heat-killed <italic toggle="yes">B. suis</italic>. To determine the level of protection conferred by immunization, mice were challenged with virulent <italic toggle="yes">B. suis</italic> via intraperitoneal or intratracheal routes, and the bacterial load was quantified post-challenge.</p></sec><sec><title>Results</title><p>Dynamic Light Scattering of the OMVs from both strains revealed the presence of spherical structures of 90-130 nm. Proteomic analysis identified 94 and 95 proteins in the wt and &#916;<italic toggle="yes">mapB</italic> OMVs, respectively, including several known <italic toggle="yes">Brucella</italic> immunogens. Both OMVs showed immunoreactivity with sera from <italic toggle="yes">Brucella</italic>-infected pigs. Intramuscular immunization of mice with both OMVs induced antigen-specific IgG in serum, with the &#916;<italic toggle="yes">mapB</italic> OMVs group showing higher titers compared to the wt OMVs group. Serum antibodies from both OMVs groups reduced <italic toggle="yes">B. suis</italic> adherence and invasion of lung epithelial cells and enhanced its phagocytosis by macrophages. Upon <italic toggle="yes">in vitro</italic> antigen stimulation, spleen cells from mice immunized with &#916;<italic toggle="yes">mapB</italic> OMVs secreted higher levels of interleukin-17 and especially gamma interferon compared to cells from mice immunized with wt OMVs, suggesting the induction of a stronger T helper 1 response in the &#916;<italic toggle="yes">mapB</italic> OMVs group. While immunization with both wt and &#916;<italic toggle="yes">mapB</italic> OMVs achieved the same level of protection following intratracheal infection with <italic toggle="yes">B. suis</italic> (p&lt;0.01), immunization with &#916;<italic toggle="yes">mapB</italic> OMVs provided higher levels of protection against intraperitoneal infection.</p></sec><sec><title>Discussion</title><p>Overall, these results demonstrate that the <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> OMVs are immunogenic and capable of inducing both cellular and humoral immune responses that protect against mucosal and systemic <italic toggle="yes">B. suis</italic> challenges.</p></sec></abstract><kwd-group><kwd>outer membrane vesicles</kwd><kwd><italic toggle="yes">Brucella suis</italic></kwd><kwd>vaccine</kwd><kwd>TAM</kwd><kwd>respiratory infection</kwd></kwd-group><funding-group><funding-statement>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants PICT 2019 02776, PICT 2021 I-INVI-00554, PICT 2018 2176, PICT 2021 I-INV-00169 from ANPCYT, grant UBACYT 20020190200361BA from Universidad de Buenos Aires.</funding-statement></funding-group><counts><fig-count count="8"/><table-count count="2"/><equation-count count="1"/><ref-count count="62"/><page-count count="17"/><word-count count="8226"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>section-in-acceptance</meta-name><meta-value>Vaccines and Molecular Therapeutics</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Brucellosis, caused by Gram-negative bacteria of the genus <italic toggle="yes">Brucella</italic>, is a worldwide zoonotic disease that leads to abortions and infertility in various domestic animals and causes a chronic, debilitating illness in humans (<xref rid="B1" ref-type="bibr">1</xref>). To date, twelve <italic toggle="yes">Brucella</italic> species with different host specificities have been identified (<xref rid="B2" ref-type="bibr">2</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>), among which <italic toggle="yes">B. abortus</italic> (mainly infecting cattle), <italic toggle="yes">B. melitensis</italic> (goats and sheep), and <italic toggle="yes">B. suis</italic> (swine) are the species with the highest zoonotic potential.</p><p>
<italic toggle="yes">B. suis</italic> is prevalent among domesticated pigs in regions such as Asia and Latin America. Although this pathogen has been nearly eliminated from commercial herds in certain areas, it persists among wild or feral swine in various regions, including North America and Europe. This persistence poses challenges for controlling brucellosis, particularly for domesticated pigs kept in outdoor environments. Moreover, clinical cases occasionally occur in hunting dogs and individuals who hunt wild boars. In some instances wild suids also transmit the infection to other livestock, such as cattle, thereby increasing the risk to human health (<xref rid="B6" ref-type="bibr">6</xref>).</p><p>Human infection can be acquired by direct contact with <italic toggle="yes">Brucella</italic>-infected animals or their products, consumption of unpasteurized dairy products, or inhalation of contaminated aerosols (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>)&#8203;. <italic toggle="yes">B. suis</italic> poses a major risk especially for slaughterhouse workers, who may become infected through aerosolized bacteria during slaughter (<xref rid="B9" ref-type="bibr">9</xref>). There is currently no approved vaccine for human use, so prevention and/or eradication of the disease in domestic animals are the main strategies to prevent human brucellosis.</p><p>Available brucellosis vaccines approved for domestic ruminants are based on live attenuated strains of <italic toggle="yes">B. abortus</italic> (<italic toggle="yes">B. abortus</italic> S19, <italic toggle="yes">B. abortus</italic> RB51) and <italic toggle="yes">B. melitensis</italic> (<italic toggle="yes">B. melitensis</italic> Rev.1), which can still cause disease in humans (<xref rid="B10" ref-type="bibr">10</xref>&#8211;<xref rid="B13" ref-type="bibr">13</xref>). Currently, no licensed and effective vaccines are available to prevent <italic toggle="yes">B. suis</italic> infection in swine in most countries where the disease is endemic. Due to the zoonotic potential of <italic toggle="yes">B. suis</italic> and the high prevalence of the infection among domestic and feral pigs in certain areas, it is crucial to develop novel and safe vaccines for swine brucellosis.</p><p>Gram-negative bacteria release, at all stages of growth, nanovesicles called Outer Membrane Vesicles (OMVs), which range in size from 20 to 300 nm (<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>). These vesicles are produced by the blebbing of the Outer Membrane (OM), with the closure of the evaginated membrane at the time of release. They are composed mainly of OM molecules along with periplasmic and cytoplasmic components and nucleic acids (<xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>). In recent years, several studies have evaluated OMVs from various Gram-negative bacteria as acellular vaccines (<xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>). These vesicles possess attractive characteristics as vaccines, including their content of diverse bacterial antigens in their natural conformation, their non-infectious nature, and the presence of numerous pathogen-associated molecular patterns (PAMPs) on their surface, which confer them immunostimulatory capacity and, in some cases, self-adjuvant activity (<xref rid="B15" ref-type="bibr">15</xref>&#8211;<xref rid="B17" ref-type="bibr">17</xref>).</p><p>Several zoonotic strains of <italic toggle="yes">Brucella</italic> spontaneously release OMVs from their surface into the environment during growth. Chemical and proteomic studies revealed that these OMVs contain several molecules related to immune protection against <italic toggle="yes">Brucella</italic> infection, including Outer Membrane Protein 16 (Omp16), Omp19, SodC, Omp25, Omp31, among others (<xref rid="B25" ref-type="bibr">25</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>). Parenteral vaccination of mice with OMVs from different <italic toggle="yes">B. melitensis</italic> strains has been shown to reduce the <italic toggle="yes">B. melitensis</italic> load after challenge (<xref rid="B25" ref-type="bibr">25</xref>). Furthermore, vaccination with OMVs from <italic toggle="yes">B. abortus</italic> 2308 and <italic toggle="yes">B. abortus</italic> RB51 protected mice from parenteral infection with virulent <italic toggle="yes">B. abortus</italic> 2308 (<xref rid="B26" ref-type="bibr">26</xref>). It remains unknown whether OMVs from <italic toggle="yes">B. suis</italic> may constitute an effective acellular vaccine against <italic toggle="yes">B. suis</italic> infection, and whether immunization with these vesicles protects against mucosally acquired infection.</p><p>It has been described in Gammaproteobacteria that the TamA and TamB proteins together form the Translocation and Assembly Module (TAM) (<xref rid="B33" ref-type="bibr">33</xref>). Initially, this system was associated with the translocation of autotransporters and other &#946;-barrel proteins across the OM (<xref rid="B33" ref-type="bibr">33</xref>). More recently it has also been linked to phospholipid homeostasis (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). The <italic toggle="yes">B. suis</italic> MapB protein is the homolog of TamB. We previously demonstrated that the <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> mutant exhibited envelope-associated phenotypes. This mutant strain showed increased sensitivity to 0.1% Triton X-100 and the cationic lipopeptide polymyxin B, and it showed an attenuated phenotype in cultured macrophages and the mouse model of infection. In addition, the &#916;<italic toggle="yes">mapB</italic> strain displayed defects in cell division, with many cells showing aberrant shapes, such as multiple septa or Y-shaped morphologies. Proteomic analyses of total membrane proteins revealed that the &#916;<italic toggle="yes">mapB</italic> mutant exhibits a reduction in the relative amounts of a subset of proteins, including members of the Omp25/31 family, compared to the wild-type strain (<xref rid="B36" ref-type="bibr">36</xref>).</p><p>It has been suggested that as bacteria grow and recycle their outer membranes, their cell walls tend to release more OMVs, particularly at the dividing septa. Moreover, it is well documented that mutants of Omps linked to the peptidoglycan layer, such as OmpA, Lpp, TolB, and Pal, exhibit an enhanced blebbing process (<xref rid="B37" ref-type="bibr">37</xref>&#8211;<xref rid="B40" ref-type="bibr">40</xref>). Therefore, we hypothesized that the presence of multiple ectopic septa and the altered levels of peptidoglycan-interacting Omps in the &#916;<italic toggle="yes">mapB</italic> strain of <italic toggle="yes">B. suis</italic> could result in an increased production of OMVs and/or changes in the antigen composition of these vesicles, potentially enhancing their efficacy as vaccine antigens.</p><p>In this study, we characterized the wt and &#916;<italic toggle="yes">mapB</italic> OMVs and evaluated their immunogenicity and protective capacity against systemic and mucosal <italic toggle="yes">B. suis</italic> challenges.</p></sec><sec sec-type="materials|methods" id="s2"><title>Material and methods</title><sec id="s2_1"><title>OMVs isolation</title><p>OMVs were obtained as previously described, with minor modifications (<xref rid="B41" ref-type="bibr">41</xref>). Briefly, <italic toggle="yes">B. suis</italic> 1330 and <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> were grown in Gerhardt Wilson minimal medium supplemented with 1% yeast extract for 48 h at 37&#176;C under agitation and harvested by centrifugation during the early stationary phase of growth. The cell-free supernatant was filtered through 0.22 &#181;m-pore-size filters to remove any remaining bacteria. Plating on Tryptic Soy Agar (TSA) confirmed the absence of viable <italic toggle="yes">B. suis</italic> in the filtered supernatant. The filtered supernatants were ultracentrifuged for 5 h at 100,000 x g and 4&#176;C. The pellet containing the OMVs was resuspended in 1 ml of sterile PBS, and the protein content was quantified using the bicinchoninic acid (BCA) method (Pierce) according to the manufacturer&#8217;s instructions. OMVs were aliquoted and stored at -20&#176;C until use. All manipulations of viable <italic toggle="yes">Brucella</italic> were performed in a biosafety level 3 (BSL3) laboratory at the Leloir Institute Foundation-IIBBA, CONICET.</p></sec><sec id="s2_2"><title>SDS-PAGE and Western Blot analysis</title><p>Isolated OMVs were separated by SDS-PAGE 15% polyacrylamide gels, stained with AgNO<sub>3</sub>, or transferred to a nitrocellulose membrane. Immunochemistry analysis for <italic toggle="yes">Brucella</italic> smooth lipopolysaccharide (S-LPS), Omp31, Omp25, Omp16, Omp19, and Omp10 was performed as described (<xref rid="B36" ref-type="bibr">36</xref>)&#8203;.</p></sec><sec id="s2_3"><title>Transmission electron microscopy (TEM)</title><p>OMVs aliquots were fixed with glutaraldehyde 2.5% and negatively strained with 2% uranyl acetate, 2% phosphotungstic acid and analyzed in a Zeiss 10 transmission electron microscope (LANAIS-MIE, Faculty of Medicine, University of Buenos Aires, UBA).</p></sec><sec id="s2_4"><title>Dynamic light scattering (DLS) measurements</title><p>DLS size distribution and hydrodynamic diameter measurements were performed at 25 &#176;C with a Zeta sizer Nano-S apparatus (Malvern Instruments) using a low-volume quartz cuvette. OMVs samples in PBS were centrifuged at 13,000 rpm for 7 min before measurements. For each sample, the analysis consisted of 7 runs of 10 s carried out in duplicate. Size distributions and hydrodynamic diameters were calculated using the general-purpose distribution analysis model of the DTS v.7.11 software (Malvern Instruments Ltd.).</p></sec><sec id="s2_5"><title>Proteomic analysis</title><p>OMVs samples were loaded in SDS-PAGE in order to separate proteins from the lipid fraction. Proteins present in the samples were digested in gel with 100 ng Trypsin (Promega V5111) in 25 mM ammonium bicarbonate pH 8.0 ON at 37&#176;C. Peptides were desalted using C18 zip tips (Merck Millipore) and eluted in 10 &#181;l of H2O:ACN: FA 40:60:0.1%. The digests were analyzed by nanoLC-MS/MS in a nanoHPLC EASY-nLC 1000 (Thermo Scientific) coupled to a QExactive Mass Spectrometer. A 120 min gradient of H2O:ACN at a flow of 33 nl/min was used with a C18 2 mm Easy Spray column &#215; 150 mm. Data Dependent MS2 method was used to fragment the top 12 peaks in each cycle. Raw data from mass spectrometry analysis was processed using the Proteome Discoverer 2.1.1.21 (Thermo Scientific) software for database searching with the SEQUEST search algorithm against the <italic toggle="yes">B. suis</italic> 1330 database. Precursor mass tolerance was set to 10 ppm and product ion tolerance to 0.05 Da. Protein hits were filtered for high confidence peptide matches with a maximum protein and peptide false discovery rate of 1% calculated by employing a reverse database strategy. A query result was only considered as significant if at least two tryptic peptides were detected with high confidence.</p><p>In order to perform Label Free Quantification (LFQ), samples were analyzed by triplicate. The area obtained for each protein was processed with the Perseus program (Max Planck Institute of Biochemistry, 1.5.5.3 version, available for free). Proteins that showed a fold change greater than 2 and a p-value below 0.05 were considered as differentially expressed.</p></sec><sec id="s2_6"><title>Animals</title><p>Female BALB/c mice (6&#8211;8 weeks old) were purchased from the National Academy of Medicine, Argentina, acclimated and randomly distributed into experimental groups. Animals were housed in a BSL3 animal facility (Operational Unit, Center for Biological Containment, National Administration of Laboratories and Health Institutes &#8220;Dr. Carlos G. Malbr&#225;n,&#8221; Argentina.), and received water and food <italic toggle="yes">ad libitum</italic>. Experiments in mice were approved by the animal care and use committee of the Faculty of Pharmacy and Biochemistry, UBA (REDEC-2022-1299-E-UBA-DCT-FFYB).</p></sec><sec id="s2_7"><title>Immunization</title><sec id="s2_7_1"><title>Experiment I</title><p>Mice were distributed into three experimental groups (n=5/group) and were immunized at 0 and 30 days by intramuscular (i.m.) injection of 20 &#181;g of <italic toggle="yes">B. suis</italic> wt OMVs (wt OMVs), 20 &#181;g of wt OMVs plus 10 &#181;g CpG-ODN 1826 adjuvant (Invivogen) or sterile physiological saline solution (SS). At different time points after immunization, blood samples were collected for antigen-specific antibody determination and the animals were subjected to protection assays (see below).</p></sec><sec id="s2_7_2"><title>Experiment II</title><p>Five animals per group were i.m. immunized with 20 &#181;g wt OMVs, 20 &#181;g <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> OMVs (&#916;<italic toggle="yes">mapB</italic> OMVs) or SS at 0 and 30 days. At different time points after immunization, blood samples were obtained for antibody quantification and spleens were harvested to assess cell-mediated immunity. Additionally, a subset of animals from each group was subjected to protection assays.</p></sec></sec><sec id="s2_8"><title>Determination of antibody response</title><p>OMVs-specific IgG and IgA levels were determined in serum samples collected at 23 and 42 days after the initial mice immunization. Mucosal-specific IgA was measured in saliva, fecal extracts, and bronchoalveolar fluid (BALF). Specific antibodies were determined using an indirect homologous ELISA. Polystyrene plates (Corning Incorporated, New York, USA) were coated with 0.5 &#181;g/well of either wt OMVs or &#916;<italic toggle="yes">mapB</italic> OMVs in PBS and incubated overnight at 4&#176;C. The plates were then washed three times with PBS containing 0.05% Tween-20 (PBS-T), followed by blocking with PBS containing 3% skim milk for 2 hours at 37&#176;C. After blocking, plates were incubated for 2 hours at 37&#176;C with the appropriate dilutions of the samples in blocking buffer. Samples from animals immunized with wt OMVs were tested on plates coated with wt OMVs, while samples from animals immunized with &#916;<italic toggle="yes">mapB</italic> OMVs were tested on plates coated with &#916;<italic toggle="yes">mapB</italic> OMVs. Following sample incubation, plates were washed three times with PBS-T and then incubated for 2 hours at 37&#176;C with the appropriate dilutions of isotype-specific goat anti-mouse horseradish peroxidase (HRP) conjugates (Sigma Aldrich, Missouri, USA; Jackson ImmunoResearch, Pennsylvania, USA). After washing with PBS-T, the reaction was developed by adding TMB substrate (BD TMB Substrate Reagent Set, BD Bioscience, San Diego, USA). After 20 minutes of incubation at room temperature, the reaction was stopped by adding 2N H<sub>2</sub>SO<sub>4</sub>, and the optical density (OD) was measured at 450 nm using a microplate reader (Multiskan). ELISA assay cut-off values were calculated as the mean OD plus 3 standard deviations (SD) from sera of non-immunized mice. Serum titers were determined as the reciprocal of the highest dilution with an OD above the cut-off value. In some figures, to facilitate comparison between groups, the OD of antigen specific -IgG at a single dilution is plotted, as indicated in the figure legend.</p><p>To assess whether <italic toggle="yes">B. suis</italic> OMV antigens can induce an antibody immune response in the natural host during natural infection, an indirect ELISA assay was performed as described above. Sera from 14 healthy and 14 diseased pigs (provided by the Brucellosis Department, DILAB, SENASA) were tested at appropriate dilution in triplicate as previously described (<xref rid="B42" ref-type="bibr">42</xref>). In this case, HRP-conjugated goat anti-swine IgG at the appropriate dilution (Jackson ImmunoResearch) was used as the secondary antibody.</p></sec><sec id="s2_9"><title>Heterologous ELISA</title><p>To evaluate the cross-reactivity of immune sera from each vaccination group, we performed heterologous indirect ELISA as previously described for homologous assays. Immune sera from each experimental group were tested against the antigen used for vaccination in the other group. To standardize comparisons between assays with different antigens, OD values were converted into Standard Deviation Scores (SDS) using the following equation:</p><disp-formula><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mtext>SDS</mml:mtext><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>ODs</mml:mtext><mml:mo>&#8722;</mml:mo><mml:mtext>ODni</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mtext>SDni</mml:mtext></mml:mrow></mml:math></disp-formula><p>ODs: OD of sample</p><p>ODni: mean OD of non-immune sera</p><p>SDni: SD of non-immune</p></sec><sec id="s2_10"><title>Anti-lipopolysaccharide antibodies</title><p>To evaluate anti-LPS response elicited by each vaccine, sera from immunized mice were tested by indirect ELISA, using plates coated with 0.1 &#181;g/mL of <italic toggle="yes">Brucella abortus</italic> LPS (provided by Ignacio Moriy&#243;n, University of Navarra, Pamplona, Spain), as described previously (<xref rid="B43" ref-type="bibr">43</xref>).</p></sec><sec id="s2_11"><title>Neutralization assay</title><p>The capacity of antibodies to neutralize bacterial adhesion and invasion of epithelial cells was evaluated as described &#8203; (<xref rid="B44" ref-type="bibr">44</xref>)&#8203;. Briefly, a suspension of <italic toggle="yes">B. suis</italic> 1330 was incubated with a 1/10 dilution of decomplemented sera from immunized mice and control groups for 1 hour at 37&#176;C with gentle agitation. After incubation, the bacterial suspension was used to infect a confluent monolayer of A549 human lung epithelial cells (ATCC CCL-185) in 96-well plates (5 x 10<sup>4</sup> cells/well) at a multiplicity of infection (MOI) of 100 for 1 hour at 37&#176;C in 5% CO<sub>2</sub>. The cells were then washed with sterile PBS, and the total bacteria associated with the cells were determined by lysis with 0.2% Triton X-100, followed by plating serial dilutions. To determine bacterial invasion, the number of intracellular viable bacteria was quantified by incubating the infected monolayers with 100 &#956;g/ml gentamicin (Sigma Aldrich) to eliminate extracellular. Following this treatment, the cells were washed and lysed. The resulting lysates were serially diluted, plated onto TSA, and incubated at 37&#176;C for 5 days. After incubation, colony-forming units (CFU) were counted to quantify bacterial viability. The number of adherent bacteria was calculated as the difference between the total bacteria associated with the cells and the intracellular bacteria.</p></sec><sec id="s2_12"><title>Opsonophagocytosis assay</title><p>The opsonophagocytosis capacity of the antibodies was assessed as described (<xref rid="B44" ref-type="bibr">44</xref>). Briefly, <italic toggle="yes">B. suis</italic> was resuspended in a 1:10 dilution of pooled sera from immunized mice of each experimental group. After 1 hour of incubation at 37&#176;C, the bacterial suspension was used to infect murine macrophages (RAW 264.7 cell line) at MOI of 100 in 96-well plates (5 x 10<sup>4</sup> cells/well) for 1 hour at 37&#176;C (time 0 p.i.). After incubation, the cells were washed and lysed to determine the number of bacteria adhered and internalized as described above.</p></sec><sec id="s2_13"><title>Characterization of cellular immune response</title><p>Antigen Presenting Cells (APCs): TIB-208&#8482; cells, a B cell lymphoma, (1 x 10<sup>6</sup> cells/ml) were cultured overnight in complete RPMI 1640 (10% fetal bovine serum, 0.05 mM 2-mercaptoethanol, 1 mM pyruvate, 2 mM L-glutamine, 100 U/ml penicillin and 100 &#956;g/ml streptomycin) either alone or in presence of heat-killed <italic toggle="yes">Brucella suis</italic> (HKBs) (1x10<sup>9</sup> CFU/ml) at 37 &#176;C 5% CO<sub>2</sub>. After incubation, cells were treated with mitomycin (25 &#956;g/ml) at 37&#176;C for 45 min and washed twice with complete RPMI 1640 medium.</p><p>
<italic toggle="yes">In vitro</italic> cytokine production: To evaluate whether vaccination with OMVs can induce a specific T cell immune response, splenocytes from immunized animals were harvested two weeks after the final immunization. These splenocytes (5 x 10<sup>7</sup> cells/ml) were cultured in 48-well plates along with APCs (1 x 10<sup>6</sup> cells/ml) pre-loaded with HKBs for 3 days at 37&#176;C with 5% CO<sub>2</sub>. After 72 h of incubation, the supernatants were collected, and the levels of gamma interferon (IFN-&#947;), interleukin-17 (IL-17), and IL-5 were measured using commercial capture ELISA kits according to the manufacturer&#8217;s instructions (BD Biosciences).</p></sec><sec id="s2_14"><title>Protection experiments</title><p>Protection experiments were conducted as previously described by our group and others (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B44" ref-type="bibr">44</xref>, <xref rid="B45" ref-type="bibr">45</xref>). Two weeks after the final immunization, mice were challenged either intraperitoneally (i.p.) with 1x10<sup>4</sup> CFU or intratracheally (i.t.) with 5x10<sup>4</sup> CFU of <italic toggle="yes">B. suis</italic> 1330. Two weeks post-challenge, mice were euthanized, and spleens (i.p. challenge) or both lungs and spleens (i.t. challenge) were aseptically collected. The organs were individually homogenized in 2 ml of sterile PBS, serially diluted ten-fold, and each dilution was plated onto two TSA plates. Plates were incubated at 37&#176;C for 3-5 days. CFU were counted and expressed as log<sub>10</sub> CFU per organ. Results for each organ were reported as the mean CFU/organ &#177; standard deviation (SD) for each group. The level of protection was calculated as the difference in mean log CFU between the vaccinated group and the SS control group.</p><p>In the absence of an approved vaccine for <italic toggle="yes">B. suis</italic> infections, the attenuated vaccine strain <italic toggle="yes">B. abortus</italic> S19 was included as a positive control in these protection experiments. A group of mice received an i.p. injection of <italic toggle="yes">B. abortus</italic> S19 (1x10<sup>4</sup> CFU/mouse) one month prior to the challenge, using the dose previously described (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B45" ref-type="bibr">45</xref>).</p><p>Protection was defined as the log10 of reduction in CFU in the spleen (i.p. and i.t. challenges) and lung (i.t. challenge) of immunized mice compared to the negative control group (SS).</p></sec><sec id="s2_15"><title>Statistical analysis</title><p>Data were tested for Shapiro-Wilk Normality and Bartlett variance homoscedasticity. For experiments with more than two groups, results were analyzed using analysis of variances (ANOVA) or Kruskal Wallis test and comparison against the control group was made with the Dunnet, Tuke&#8217;y or Dunn post-test, respectively. An unpaired <italic toggle="yes">t-test</italic> was used for comparison between two experimental groups. All statistical analyses were performed with the GraphPad Prism software (San Diego, CA).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3_1"><title>
<italic toggle="yes">B. suis</italic> OMVs isolation and characterization</title><p>We have previously reported the isolation of OMVs from <italic toggle="yes">B. abortus</italic> cultured in Gerhardt Wilson minimal medium (<xref rid="B41" ref-type="bibr">41</xref>). Due to its performance, the same method was applied in this work with minor modifications. OMVs fractions from <italic toggle="yes">B. suis</italic> wt and <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> showed similar protein concentrations (approximately 8 mg protein/L culture) and spherical shapes, including a double membrane &#8203;when observed by TEM (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1A</bold>
</xref>). Both OMVs samples showed a single particle population by DLS, which corresponded to a hydrodynamic diameter (HD) of 119 &#177; 9 and 105 &#177; 19 nm for the wt and &#916;<italic toggle="yes">mapB</italic> OMVs, respectively (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1B</bold>
</xref>). The HD values agree with the size obtained by analytical TEM for both the wt and &#916;<italic toggle="yes">mapB</italic> OMVs (122.8 &#177; 34.54 nm and 123.0 &#177; 43.95 nm, respectively).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Characterization of <italic toggle="yes">B. suis</italic> 1330 and <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> OMVs. wt OMVs and OMVs &#916;<italic toggle="yes">mapB</italic> samples were analyzed by Electronic Microscopy <bold>(A)</bold> and Dynamic Light Scattering <bold>(B)</bold>, separated by SDS-PAGE 15% polyacrylamide gels <bold>(C)</bold> and transferred to a nitrocellulose membrane for immunoblot analysis with specific monoclonal antibodies anti-<italic toggle="yes">Brucella</italic> LPS, Omp31, Omp25, Omp19, Omp16 and Omp10 proteins <bold>(D)</bold>. Label Free Quantification (LFQ) proteomic assay was performed and samples were analyzed by triplicate. For each couple of samples, a volcano plot was constructed with &#8211;log p-value (-Log Student T-test p-value wt_&#916;<italic toggle="yes">mapB</italic>) plotted on the y-axis versus Student T-test Difference wt_&#916;<italic toggle="yes">mapB</italic> in the x axis <bold>(E)</bold>. Proteins with a fold change greater than 2 and a p-value below 0.05 were considered as differentially expressed.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1501791-g001.jpg"/></fig><p>Identifying proteins present in OMVs is crucial to understand their immunogenic properties. The SDS-PAGE analysis of wt and &#916;<italic toggle="yes">mapB</italic> OMVs samples revealed a similar protein pattern (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1C</bold>
</xref>). Subsequent OMVs immunoblot analysis with specific monoclonal antibodies confirmed the presence of OM components such as <italic toggle="yes">Brucella</italic> S-LPS, Omp31, Omp25, Omp19, Omp16 and Omp10 proteins in both OMVs types (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1D</bold>
</xref>).</p><p>To assess the specific protein repertoire of the wt and &#916;<italic toggle="yes">mapB</italic> vesicles a LFQ proteomic analysis was performed. A total of 94 and 95 hits were detected in the wt and &#916;<italic toggle="yes">mapB</italic> OMVs, respectively, with 51 and 46 corresponding to membrane proteins. Proteomic data analysis revealed the presence of BLS, Omp16, Omp19, Omp31, Omp25, SOD, GroEL and bacterioferritin proteins in OMVs of both strains (<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Table S1</bold>
</xref>), all of which have been previously identified as promising <italic toggle="yes">Brucella</italic> vaccine candidates &#8203; (<xref rid="B28" ref-type="bibr">28</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>)&#8203;. <xref rid="f1" ref-type="fig">
<bold>Figure&#160;1E</bold>
</xref> shows a Volcano plot highlighting differentially expressed peptides, with the detailed information summarized in <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>. LFQ proteomic analysis revealed a reduction in the expression of Omp10 and an OmpA family protein in the &#916;<italic toggle="yes">mapB</italic> OMVs (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). Given the alterations previously observed in the <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> cell envelope &#8203; (<xref rid="B36" ref-type="bibr">36</xref>), these results are particularly interesting since both OM proteins play a role in proper OM biogenesis. Conversely, six proteins were found to be increased in the &#916;<italic toggle="yes">mapB</italic> OMVs, including one uncharacterized protein. Two of these proteins, an ABC transporter and a TRAP solute transporter, are periplasmic proteins predicted to be involved in amino acid uptake. The other three proteins were identified as a YaeC family lipoprotein, a periplasmic peptidyl-prolyl cis-trans isomerase with an N- terminal SurA domain and a cytosolic ribosomal protein. The increased presence of an ABC transporter and a TRAP solute transporter suggests, therefore, a compensatory strategy for nutrient uptake and homeostasis in the absence of MapB, potentially enhancing bacterial survival and virulence under stress. Moreover, the upregulation of the YaeC family lipoprotein likely supports membrane integrity and compensates for defects in outer membrane structure caused by the loss of MapB. In addition, the increased expression of a periplasmic peptidyl-prolyl cis-trans isomerase with a SurA domain highlights a possible upregulation of protein folding and assembly mechanisms to counteract disruptions in &#916;<italic toggle="yes">mapB</italic> cell envelope. Taken together, these findings suggest that the &#916;<italic toggle="yes">mapB</italic> strain activates compensatory pathways to maintain membrane function and bacterial adaptability.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Label free quantification proteomic assay.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" colspan="3" align="left" rowspan="1">Reduced protein levels in &#916;<italic toggle="yes">mapB</italic> OMVs</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1">ID</th><th valign="middle" align="center" rowspan="1" colspan="1">Description</th><th valign="middle" align="center" rowspan="1" colspan="1">Subcellular localization</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">1. A0A0H3G3E6</td><td valign="middle" align="center" rowspan="1" colspan="1">OmpA family protein BS1330_I1200 (motB)</td><td valign="middle" align="center" rowspan="1" colspan="1">OM</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">2. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="P0A3N9">P0A3N9</ext-link></td><td valign="middle" align="center" rowspan="1" colspan="1">Outer membrane lipoprotein Omp10</td><td valign="middle" align="center" rowspan="1" colspan="1">OM</td></tr><tr><th valign="bottom" colspan="3" align="left" rowspan="1">Increased protein levels in &#916;<italic toggle="yes">mapB</italic> OMVs</th></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">1. A0A0H3G576</td><td valign="middle" align="center" rowspan="1" colspan="1">Uncharacterized protein. DUF922 domain-containing Zn-dependent protease</td><td valign="middle" align="center" rowspan="1" colspan="1">IM/C</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">2. A0A0H3G9A1</td><td valign="middle" align="center" rowspan="1" colspan="1">YaeC family lipoprotein nlpA lipoprotein</td><td valign="middle" align="center" rowspan="1" colspan="1">IM</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">3. A0A0H3G608</td><td valign="middle" align="center" rowspan="1" colspan="1">Peptidyl-prolyl cis-trans isomerase (surA domain)</td><td valign="middle" align="center" rowspan="1" colspan="1">IM</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">4. A0A0H3G440</td><td valign="middle" align="center" rowspan="1" colspan="1">TRAP transporter solute receptor TAXI family protein</td><td valign="middle" align="center" rowspan="1" colspan="1">P</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">5. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="Q8G3D4">Q8G3D4</ext-link></td><td valign="middle" align="center" rowspan="1" colspan="1">Leu/Ile/Val-binding protein homolog. ABC transporter quorum sensing pathway</td><td valign="middle" align="center" rowspan="1" colspan="1">P</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">6. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="P59180">P59180</ext-link></td><td valign="middle" align="center" rowspan="1" colspan="1">30S ribosomal protein S3 rpsC</td><td valign="middle" align="center" rowspan="1" colspan="1">IM/C</td></tr></tbody></table><table-wrap-foot><fn><p>ID: Uniprot protein identification. Subcellular localization: determined by GnegmPloc online server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.csbio.sjtu.edu.cn/bioinf/Gneg-multi/" ext-link-type="uri">http://www.csbio.sjtu.edu.cn/bioinf/Gneg-multi/</ext-link>); OM, Outer Membrane; IM, Inner Membrane; C, Citosolic; P, Periplasmic.</p></fn></table-wrap-foot></table-wrap><p>To determine whether <italic toggle="yes">B. suis</italic> OMVs antigens are immunogenic during infection of the natural host, we evaluated the presence of specific antibodies in sera from 14 healthy pigs and 14 pigs naturally infected with <italic toggle="yes">B. suis</italic>. IgG levels against both wt OMVs and &#916;<italic toggle="yes">mapB</italic> OMVs were significantly higher in the sera of infected animals compared to healthy animals (<xref rid="f2" ref-type="fig">
<bold>Figure&#160;2</bold>
</xref>). These results indicate that antigens present in both OMVs induce an antibody response during natural infection.</p><fig position="float" id="f2" orientation="portrait"><label>Figure&#160;2</label><caption><p>Specific IgG anti-wt OMVs <bold>(A)</bold> and anti-&#916;<italic toggle="yes">mapB</italic> OMVs <bold>(B)</bold> from sera of sick (Infected) and healthy (Non-infected) natural pigs were determined by ELISA. Values express OD450 nm of sera 1/100 dilution. Data were analyzed by t-test followed by Mann Whitney post-test; ****p&lt;0.0001 differences were calculated concerning the Non-Infected group. All results are representative of at least two independent experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1501791-g002.jpg"/></fig></sec><sec id="s3_2"><title>OMVs from <italic toggle="yes">B. suis</italic> are immunogenic</title><p>As bacterial-derived products, OMVs inherently contain a range of molecules, including proteins and lipids, which activate the innate immune system. Prior studies have evaluated OMVs from pathogenic bacteria as vaccine platforms, demonstrating their ability to enhance immune responses, thus supporting their potential in vaccine development (<xref rid="B20" ref-type="bibr">20</xref>&#8211;<xref rid="B26" ref-type="bibr">26</xref>). To examine the immunogenic properties of OMVs isolated under our specific conditions, we assessed whether they could elicit significant immune responses when administered alone or if they required co-administration with adjuvants. For this purpose, mice were immunized by the i.m. route with wt OMVs alone or in combination with CpG-ODN adjuvant. wt OMVs immunization induced a specific humoral immune response both in the presence and absence of adjuvant (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3A</bold>
</xref>). Antibody levels increased significantly after the second immunization (30 days) in both experimental groups. However, no significant differences in serum IgG levels were observed between the wt OMVs and wt OMVs + CpG groups.</p><fig position="float" id="f3" orientation="portrait"><label>Figure&#160;3</label><caption><p>Immunization with wt OMVs induces a humoral immune response and reduces the splenic bacterial load. Mice were i.m. immunized with wt OMVs (20 &#181;g), wt OMVs (20 &#181;g) + CpG (10 &#181;g), or saline solution (SS) at 0 and 30 days. At 23 and 42 days levels of specific anti-OMVs IgG antibodies in sera were measured by indirect ELISA <bold>(A)</bold>. Results are expressed as mean OD<sub>450nm</sub> &#177; SD of sera 1/100 dilution. Immunized mice were challenged through the i.p. route with <italic toggle="yes">B. suis</italic> 1330. CFU were measured in spleens at 20 days post-challenge <bold>(B)</bold>. Data were analyzed by two-way ANOVA followed by Dunnett&#180;s post-test, *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001 differences were calculated concerning the control group (SS). All results are representative of at least two independent experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1501791-g003.jpg"/></fig><p>Following i.p. challenge with virulent <italic toggle="yes">B. suis</italic>, animals vaccinated with wt OMVs exhibited a significantly reduced splenic bacterial load compared to negative control (SS) (<xref rid="f3" ref-type="fig">
<bold>Figure&#160;3B</bold>
</xref>). No significant differences in the number of viable bacteria in the spleen were observed between animals immunized with OMVs alone or with OMVs + CpG. Taken together, these results demonstrate that OMVs obtained under our conditions are immunogenic when administered by the i.m. route, and partially protect mice from systemic <italic toggle="yes">B. suis</italic> infection.</p></sec><sec id="s3_3"><title>&#916;<italic toggle="yes">mapB</italic> OMVs induces a stronger humoral immune response compared to OMVs</title><p>To evaluate the immunogenicity of <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> OMVs and to compare the humoral immune responses elicited by both wt and &#916;<italic toggle="yes">mapB</italic> OMVs, we assessed the production of specific antibodies in mice immunized via the i.m. route without adjuvant. Antibody levels were measured using an indirect ELISA against the respective immunogen (homologous ELISA). Both OMVs formulations induced specific IgG in serum (<xref rid="f4" ref-type="fig">
<bold>Figures&#160;4A, B</bold>
</xref>). Notably, the serum IgG titers were significantly higher in animals vaccinated with &#916;<italic toggle="yes">mapB</italic> OMVs compared to those immunized with wt OMVs (median: 1600 for &#916;<italic toggle="yes">mapB</italic> OMVs vs. median: 400 for wt OMVs).</p><fig position="float" id="f4" orientation="portrait"><label>Figure&#160;4</label><caption><p>Antigen-specific serum IgG. Mice (n=5/group) were i.m. immunized with wt OMVs (20 &#181;g), &#916;<italic toggle="yes">mapB</italic> OMVs (20 &#181;g), or saline solution (SS) at 0 and 30 days. Blood samples were collected at 23 and 42 days and levels of specific anti-wt OMVs or anti-&#916;<italic toggle="yes">mapB</italic> OMVs IgG antibodies were measured by indirect homologous ELISA <bold>(A, B)</bold>. Data were analyzed by two-way ANOVA followed by the Dunnett test to compare against non-immune sera, and the Sidak test to compare the same group between times. Results are expressed as mean OD<sub>450nm</sub> &#177; SD of sera 1/100 dilution. Sera cross-reactivity against heterologous OMVs was evaluated by indirect ELISA <bold>(C)</bold>. Results are expressed as standard deviation score (SDS), and Kruskal-Wallis statistical analysis followed by Dunn&#180;s post-test was applied. Specific IgG anti- <italic toggle="yes">Brucella</italic> LPS were measured in serum collected at 42 days of wt OMVs and &#916;<italic toggle="yes">mapB</italic> OMVs groups by indirect ELISA <bold>(D)</bold>. Results are expressed as mean OD450nm &#177; SD of sera 1/100 dilution. Data were analyzed by one-way ANOVA followed by the Tukey&#8217;s <italic toggle="yes">post hoc</italic> test to compare between groups.*p&lt;0.05, **p&lt; 0.01, ***p&lt; 0.001, ****p&lt;0.0001 vs. non-immune.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1501791-g004.jpg"/></fig><p>To elucidate whether the higher antibody titer of animals immunized with &#916;<italic toggle="yes">mapB</italic> OMVs was related to an increased ability of these vesicles to adhere to the ELISA plate, we assessed the cross-reactivity of sera from both vaccinated groups toward both wt and &#916;<italic toggle="yes">mapB</italic> OMVs by heterologous indirect ELISA. Serum IgG reactivity induced by wt OMVs vaccination was higher against the &#916;<italic toggle="yes">mapB</italic> OMVs than against the homologous antigen (wt OMVs) (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4C</bold>
</xref>). In contrast, serum antibodies from mice immunized with &#916;<italic toggle="yes">mapB</italic> OMVs showed similar recognition toward both OMVs types (<xref rid="f4" ref-type="fig">
<bold>Figure&#160;4C</bold>
</xref>). These results demonstrate that there is no differential binding to the ELISA plate between both OMVs and suggest immunogenic differences between wt and &#916;<italic toggle="yes">mapB</italic> OMVs instead.</p><p>To further characterize the immune response elicited by these vaccines, we also assessed anti-<italic toggle="yes">Brucella</italic> LPS antibodies in the sera of both vaccinated groups using an indirect ELISA. As shown in <xref rid="f4" ref-type="fig">
<bold>Figure&#160;4D</bold>
</xref>, vaccination with both OMVs types induced the production of anti-LPS antibodies, with significantly higher levels observed in the &#916;<italic toggle="yes">mapB</italic> OMVs group. These findings reinforce the notion that &#916;<italic toggle="yes">mapB</italic> OMVs elicit a stronger humoral immune response against <italic toggle="yes">Brucella</italic> antigens compared to wt OMVs, highlighting their enhanced immunogenic potential.</p><p>In parallel, immunization with &#916;<italic toggle="yes">mapB</italic> OMVs induced a greater increase in specific IgA titers in serum (median: 400) than wt OMVs (median: 100) (<xref rid="f5" ref-type="fig">
<bold>Figure&#160;5A</bold>
</xref>). Moreover, a slight increase of specific IgA levels in BALF and saliva was detected only in mice vaccinated with &#916;<italic toggle="yes">mapB</italic> OMVs as compared with the control group (SS) (<xref rid="f5" ref-type="fig">
<bold>Figures&#160;5B, C</bold>
</xref>).</p><fig position="float" id="f5" orientation="portrait"><label>Figure&#160;5</label><caption><p>Specific serum and mucosal IgA. Mice were immunized with wt OMVs (20 &#956;g), &#916;<italic toggle="yes">mapB</italic> OMVs (20 &#956;g), or saline solution (SS) at 0 and 30 days. Two weeks after the last immunization sera <bold>(A)</bold>, saliva <bold>(B)</bold>, and BALF <bold>(C)</bold> samples were obtained, and indirect ELISA measured specific IgA antibodies levels. Data were analyzed by one-way ANOVA followed by Dunnett&#180;s test or by unpaired <italic toggle="yes">t-test</italic>. Data are expressed as mean OD<sub>450nm</sub> &#177; SE. **p&lt;0.01; ****p&lt;0.0001 vs Non-Immune or SS.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1501791-g005.jpg"/></fig><p>To assess the functionality of the specific serum antibodies induced by immunization, the neutralization capacity of these antibodies was evaluated. Serum antibodies from mice immunized with wt or &#916;<italic toggle="yes">mapB</italic> OMVs significantly reduced bacterial adhesion and invasion to A549 epithelial cells monolayer compared to serum from the control group (<xref rid="f6" ref-type="fig">
<bold>Figures&#160;6A, B</bold>
</xref>). However, no significant differences were observed in this regard between sera from both OMVs-immunized groups. The ability of the serum specific antibodies to promote phagocytosis was also assessed. The uptake of <italic toggle="yes">B. suis</italic> by macrophages was significantly increased when bacteria were pre-incubated with sera from both OMVs-immunized groups as compared to sera from control mice (<xref rid="f6" ref-type="fig">
<bold>Figure&#160;6C</bold>
</xref>).</p><fig position="float" id="f6" orientation="portrait"><label>Figure&#160;6</label><caption><p>Serum antibodies&#8217; functionality. Mice (n=5/group) were i.m. immunized with wt OMVs (20 &#181;g), &#916;<italic toggle="yes">mapB</italic> OMVs (20 &#181;g), or saline solution (SS) at 0 and 30 days. Blood samples were collected at 23 and 42 days. Antibodies&#8217; capacity to neutralize <italic toggle="yes">B. suis</italic> 1330 adhesion and invasion to A549 epithelial cells line was performed. Total bacteria adhered to the cell monolayer <bold>(A)</bold> and internalized bacteria <bold>(B)</bold> were determined. The ability of anti-OMVs antibodies to facilitate bacterial opsonophagocytosis was also determined. <italic toggle="yes">B. suis</italic> were preincubated with immune serum as described and added to macrophages for 1 h, then intracellular bacteria were determined for CFU counting <bold>(C)</bold>. Results are expressed as log CFU/ml. **p&lt;0.01, *p&lt;0.05 vs SS. Results are expressed as mean &#177; SD of duplicate measurements from three independent.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1501791-g006.jpg"/></fig></sec><sec id="s3_4"><title>Characterization of the cellular immune response</title><p>To characterize the T helper cellular immune response against <italic toggle="yes">B. suis</italic> antigens, spleen cells from immunized mice were stimulated <italic toggle="yes">in vitro</italic> with APCs pre-loaded with HKBs, and the cytokines IFN-&#947;, IL-17, and IL-5 were measured in the culture supernatants. Stimulation of spleen cells from the wt or &#916;<italic toggle="yes">mapB</italic> OMVs groups significantly increased the secretion of IFN-&#947; and IL-17 compared to the control (SS) group (<xref rid="f7" ref-type="fig">
<bold>Figures&#160;7A, B</bold>
</xref>). Notably, spleen cells from the &#916;<italic toggle="yes">mapB</italic> OMVs group secreted higher levels of IFN-&#947; and IL-17 than those from the wt OMV group (<xref rid="f7" ref-type="fig">
<bold>Figures&#160;7A, B</bold>
</xref>). Interestingly, IL-5 was undetectable in stimulated spleen cells from both wt and &#916;<italic toggle="yes">mapB</italic> OMVs-vaccinated mice. These results suggest that vaccination with both wt and &#916;<italic toggle="yes">mapB</italic> OMVs induces a mixed Th1 and Th17 response against <italic toggle="yes">Brucella</italic>.</p><fig position="float" id="f7" orientation="portrait"><label>Figure&#160;7</label><caption><p>Cellular immune response. Two weeks after the last immunization, spleens from immunized mice (n=5/group) were collected and cell suspensions were cultured with APC pre-loaded with HKBs, or RPMI medium. At 72 h post-stimulation culture supernatants were harvested to measure levels of IL-17, and IFN-&#947; by ELISA <bold>(A, B)</bold>. Results were analyzed by two-way ANOVA followed by Dunnett&#8217;s multi-comparison test, and are expressed as the mean concentration &#177; SD of duplicate measurements from three independent experiments. (****p &lt; 0.0001 vs RPMI 1640).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1501791-g007.jpg"/></fig></sec><sec id="s3_5"><title>Immunization with &#916;<italic toggle="yes">mapB</italic> OMVs induces systemic and mucosal protection</title><p>To evaluate the efficiency of OMV vaccination in protecting against <italic toggle="yes">B. suis</italic> infection, immunized animals were challenged via the i.p. route with virulent <italic toggle="yes">B. suis</italic>. Immunizations with both OMVs reduced the spleen bacterial load after <italic toggle="yes">Brucella</italic> infection compared to the control group (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>). Notably, vaccination with &#916;<italic toggle="yes">mapB</italic> OMVs conferred significantly greater protection, reducing the bacterial load by 2.113 log compared to 1.673 log observed with wt OMVs (p&lt;0.05). For reference, the S19 vaccine strain, included as a positive control, reduced the bacterial load by 1.474 log (p&lt;0.05 compared to &#916;<italic toggle="yes">mapB</italic> OMVs). Although this strain is not an approved vaccine for preventing <italic toggle="yes">B. suis</italic> infection, a recent study has demonstrated its safety and immunogenicity in pregnant pigs (<xref rid="B46" ref-type="bibr">46</xref>), emphasizing its potential as a candidate vaccine against <italic toggle="yes">B. suis</italic> in swine.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table&#160;2</label><caption><p>Protection from virulent <italic toggle="yes">B. suis</italic> challenge in mice.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="middle" colspan="4" align="left" rowspan="1">Intraperitoneal challenge</th></tr><tr><th valign="middle" align="center" rowspan="1" colspan="1"/><th valign="middle" align="center" rowspan="1" colspan="1">Experimental group</th><th valign="middle" align="center" rowspan="1" colspan="1">log CFU/organ<break/>(mean &#177; SD)</th><th valign="middle" align="center" rowspan="1" colspan="1">Protection level<break/>(log)</th></tr></thead><tbody><tr><td valign="middle" rowspan="4" align="center" colspan="1">Spleen</td><td valign="top" align="left" rowspan="1" colspan="1">SS</td><td valign="top" align="center" rowspan="1" colspan="1">5.421 &#177; 0.093<sup>a</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">wt OMVs</td><td valign="top" align="center" rowspan="1" colspan="1">3.748 &#177; 0.180<sup>b</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">1.673</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#916;<italic toggle="yes">mapB</italic> OMVs</td><td valign="top" align="center" rowspan="1" colspan="1">3.308 &#177; 0.039<sup>c</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">2.113</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. abortus</italic> S19</td><td valign="top" align="center" rowspan="1" colspan="1">3.947 &#177; 0.420<sup>b</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">1.474</td></tr><tr><th valign="middle" colspan="4" align="left" rowspan="1">Intratracheal challenge</th></tr><tr><td valign="middle" rowspan="4" align="center" colspan="1">Spleen</td><td valign="top" align="left" rowspan="1" colspan="1">SS</td><td valign="top" align="center" rowspan="1" colspan="1">5.281 &#177; 0.185<sup>a</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">wt OMVs</td><td valign="top" align="center" rowspan="1" colspan="1">4.108 &#177; 0.165<sup>b</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">1.173</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#916;<italic toggle="yes">mapB</italic> OMVs</td><td valign="top" align="center" rowspan="1" colspan="1">4.159 &#177; 0.104<sup>b</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">1.122</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. abortus</italic> S19</td><td valign="top" align="center" rowspan="1" colspan="1">4.058 &#177; 0.489<sup>b</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">1.223</td></tr><tr><td valign="middle" rowspan="4" align="center" colspan="1">Lung</td><td valign="top" align="left" rowspan="1" colspan="1">SS</td><td valign="top" align="center" rowspan="1" colspan="1">5.493 &#177; 0.129<sup>a</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.00</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">wt OMVs</td><td valign="top" align="center" rowspan="1" colspan="1">4.847 &#177; 0.097<sup>b</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.646</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#916;<italic toggle="yes">mapB</italic> OMVs</td><td valign="top" align="center" rowspan="1" colspan="1">4.822 &#177; 0.135<sup>b</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.671</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic toggle="yes">B. abortus</italic> S19</td><td valign="top" align="center" rowspan="1" colspan="1">3.911 &#177; 0.187<sup>c</sup>
</td><td valign="top" align="center" rowspan="1" colspan="1">1.582</td></tr></tbody></table><table-wrap-foot><fn><p>BALB/c mice from wt OMVs, &#916;<italic toggle="yes">mapB</italic> OMVs <italic toggle="yes">B. abortus</italic> S19 and saline groups (SS) were challenged through the i.p. and i.t. route with <italic toggle="yes">B. suis</italic> 1330. CFU were measured in spleens and lungs at 20 days post-infection. Values are expressed as mean CFU/organ &#177; SD for each vaccine group of duplicate measurements from two independent experiments. Significant differences between groups were analyzed by one-way ANOVA followed by Tukey&#8217;s test statistical analysis and are indicated by lowercase letters, at p &lt;0.05.</p></fn></table-wrap-foot></table-wrap><p>To assess whether the immune response triggered by i.m. immunization with these OMVs was able to protect against mucosal infection, immunized mice were challenged via i.t. route with <italic toggle="yes">B. suis</italic>. Vaccination with both OMVs significantly reduced <italic toggle="yes">Brucella</italic> spleen load, showing protection levels like those observed in the S19 vaccine group (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>). Vaccination with both OMVs also significantly reduced (0.646 and 0.671 respectively) the lung <italic toggle="yes">B. suis</italic> burden compared to the control group (SS), albeit to lower levels than the S19 vaccine (1.582) (<xref rid="T2" ref-type="table">
<bold>Table&#160;2</bold>
</xref>).</p><p>Together these results suggest that immunization with both OMVs protects against i.p. challenge, and partially against i.t. challenge with <italic toggle="yes">B. suis</italic>.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>
<italic toggle="yes">B. suis</italic> is the etiological agent of swine brucellosis, a widely distributed zoonotic disease for which there are still no approved vaccines. OMVs have garnered significant attention as potential vaccine candidates due to their ability to stimulate robust immune responses. These vesicles, naturally released by many Gram-negative bacteria, contain a variety of surface-exposed antigens and PAMPs, which can activate both innate and adaptive immune systems. The presence of multiple immunogenic components, such as LPS, Omps, and other molecular motifs, allows OMVs to act as a powerful platform for immunization, providing broad protection against a range of bacterial pathogens. This inherent diversity in antigenic profiles, combined with their ability to mimic bacterial infections without the risk of virulence, makes OMVs an attractive option for developing vaccines, especially in the context of pathogens that lack effective vaccine candidates (<xref rid="B17" ref-type="bibr">17</xref>&#8211;<xref rid="B24" ref-type="bibr">24</xref>). Recently, we demonstrated that <italic toggle="yes">B. suis</italic> MapB protein is essential for OM stability and is involved in cell division &#8203; (<xref rid="B36" ref-type="bibr">36</xref>)&#8203;. In this work, we characterized OMVs from <italic toggle="yes">B. suis</italic> wt and <italic toggle="yes">B. suis</italic> &#916;<italic toggle="yes">mapB</italic> and, for the first time, evaluated the potential of these vesicles as an acellular vaccine against <italic toggle="yes">Brucella</italic> infection.</p><p>To obtain better yields of OMVs, we employed a production strategy previously described in our laboratory, with minor modifications (<xref rid="B41" ref-type="bibr">41</xref>)&#8203;. OMVs obtained from both strains under these conditions showed spherical shapes with bilayer-double membranes and ranged in size from 90 to 100 nm. These OMVs have a similar size to previously reported OMVs from <italic toggle="yes">B. abortus</italic> and <italic toggle="yes">B. melitensis</italic> (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B41" ref-type="bibr">41</xref>), albeit slightly larger than that of OMVs isolated from <italic toggle="yes">B. suis</italic> grown on solid medium (47 nm) &#8203; (<xref rid="B27" ref-type="bibr">27</xref>)&#8203;. It is worth noting that the characteristics and composition of OMVs can vary depending on the methods used for isolation and purification, culture medium, conservation techniques, and bacterial stress conditions &#8203; (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>)&#8203;. Therefore, the variations in growth conditions across these studies could account for the differences in OMVs size.</p><p>Proteomic analysis of OMVs isolated from the wt and &#916;<italic toggle="yes">mapB</italic> strains revealed the presence of 94 and 95 proteins, respectively, with similar subcellular localization in both strains. We previously demonstrated that MapB deficiency in the mutant strain did not lead to an extensive alteration of Omp abundance in total membranes, but rather caused a reduction in the relative amounts of a subset of proteins, including Omps &#8203; (<xref rid="B36" ref-type="bibr">36</xref>)&#8203;. Notably, under the assayed conditions, the proteomic approach showed a significant reduction in the abundance of Omp10 and a protein from the OmpA family (BR1204) in &#916;<italic toggle="yes">mapB</italic> OMVs. Previous studies have indicated that deletion of the Omp10 gene in <italic toggle="yes">B. abortus</italic> affects its survival <italic toggle="yes">in vivo</italic> but does not impact on its membrane properties &#8203; (<xref rid="B47" ref-type="bibr">47</xref>)&#8203;. Regarding OmpA, it is interesting to note that the OmpA homologue from the gammaproteobacterium <italic toggle="yes">Pseudomonas aeruginosa</italic> possesses a conserved domain that anchors the OM to the peptidoglycan, playing a crucial role in OMVs biogenesis (<xref rid="B48" ref-type="bibr">48</xref>)&#8203;. Furthermore, down-regulation of the OmpA protein has been found to enhance OMVs production (<xref rid="B48" ref-type="bibr">48</xref>)&#8203;. Therefore, OmpA deficiency could potentially contribute to the instability of OM in the &#916;<italic toggle="yes">mapB</italic> mutant strain of <italic toggle="yes">B. suis</italic>.</p><p>Interestingly, SurA, a periplasmic peptidyl-prolyl cis-trans isomerase protein, is included among the increased proteins in &#916;<italic toggle="yes">mapB</italic> OMVs. SurA is both a folding catalyst and a chaperone in &#946;-barrel Omps biogenesis and as such plays a key role in cell envelope homeostasis (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B50" ref-type="bibr">50</xref>)&#8203;. In addition, SurA is also required for full virulence of uropathogenic <italic toggle="yes">Escherichia coli, Shigella</italic> and <italic toggle="yes">Salmonella</italic> spp (<xref rid="B49" ref-type="bibr">49</xref>). A previous study showed that immunization with recombinant SurA from <italic toggle="yes">B. abortus</italic> induces a Th1/Th2 immune response and confers partial protection against <italic toggle="yes">B. abortus</italic> challenge (<xref rid="B45" ref-type="bibr">45</xref>); so, the increased levels of this protein may confer &#916;<italic toggle="yes">mapB</italic> OMVs an advantage as immunogen.</p><p>Among the proteins shared by OMVs of wt and &#916;<italic toggle="yes">mapB</italic> strains, we identified BLS, Omp16, Omp19, Omp31, Omp25, SOD, GroEL and bacterioferritin, which have been previously recognized as either virulence factors or protective immunogens against <italic toggle="yes">Brucella</italic> (<xref rid="B29" ref-type="bibr">29</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B51" ref-type="bibr">51</xref>). The presence in the OMVs of the mentioned Omps was confirmed by Western Blot. Supporting our findings, a study by Boigegrain et&#160;al. in 2004 showed the presence of Omp31 and Omp25 proteins in OMVs from <italic toggle="yes">B. suis</italic> (<xref rid="B52" ref-type="bibr">52</xref>). Furthermore, in a recent study, Ruiz Palma et&#160;al. identified immunogenic proteins, such as Omp16, Omp25, Omp31, and SodC in the proteome of OMVs from <italic toggle="yes">B. suis</italic> 1330 (<xref rid="B26" ref-type="bibr">26</xref>). Omp25 is required for intracellular survival of <italic toggle="yes">Brucella</italic> in macrophages (<xref rid="B53" ref-type="bibr">53</xref>). In addition, <italic toggle="yes">B. suis</italic> Omp25 inhibits TNF&#945; production, a key cytokine in bacterium control, by inducing specific microRNA expression in macrophages (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B53" ref-type="bibr">53</xref>). Omp31 is involved in <italic toggle="yes">B. melitensis</italic> membrane stability and the inhibition of TNF&#945;-induced macrophage apoptosis (<xref rid="B54" ref-type="bibr">54</xref>). Of note, it was reported that Omp16 and Omp19 activate dendritic cells and induce immune protection similar to that elicited by the <italic toggle="yes">B. abortus</italic> S19 vaccine (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). In this study we showed that OMVs from both strains also contain SOD and GroEL. These proteins play a role in bacterial resistance mechanisms to macrophagic microbicide activity. While previous studies have shown that immunization with GroEL does not generate a protective response against <italic toggle="yes">Brucella</italic> (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B55" ref-type="bibr">55</xref>), vaccination with SOD has demonstrated effective immune protection in the natural host (<xref rid="B51" ref-type="bibr">51</xref>).</p><p>The presence of immune-protective proteins in OMVs from <italic toggle="yes">B. suis</italic> makes them promising candidates for an acellular vaccine. Importantly, both wt and &#916;<italic toggle="yes">mapB</italic> OMVs were recognized by serum antibodies from infected pigs, confirming their immunogenicity in the natural host.</p><p>The present study showed that, similarly to OMVs from <italic toggle="yes">B. abortus</italic> and <italic toggle="yes">B. melitensis</italic> (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>),&#8203; OMVs isolated from <italic toggle="yes">B. suis</italic> can stimulate the immune response and confer protection in mice. Vaccination with wt OMVs alone generated serum specific antibodies and significantly reduced <italic toggle="yes">B. suis</italic> burden in the spleen of infected mice. Notably, the addition of CpG ODN adjuvant to the vaccine formulation did not enhance antibody levels or improve the protection achieved by OMVs alone. These findings indicate that OMVs from <italic toggle="yes">B. suis</italic> are immunogenic and protective at the given dose, without requiring additional adjuvants.</p><p>The absence of MapB in <italic toggle="yes">B. suis</italic> causes membrane instability, which may confer distinct immunogenic characteristics to the OMVs released by the mutant strain. In this study, we investigated the humoral immune response induced by vaccination with OMVs from both wt and &#916;<italic toggle="yes">mapB</italic> strains. Immunization with &#916;<italic toggle="yes">mapB</italic> OMVs produced higher serum levels of specific IgG and IgA compared to immunization with wt OMVs. This difference was not due to a methodological artifact, as sera from animals immunized with &#916;<italic toggle="yes">mapB</italic> OMVs recognized both wt and &#916;<italic toggle="yes">mapB</italic> OMVs similarly. However, sera from animals vaccinated with wt OMVs exhibited stronger recognition of mutant OMVs. Furthermore, &#916;<italic toggle="yes">mapB</italic> OMVs induced significantly higher levels of <italic toggle="yes">Brucella</italic> LPS-specific antibodies compared to wt OMVs, highlighting their enhanced capacity to elicit humoral immune responses against this key <italic toggle="yes">Brucella</italic> antigen.</p><p>These results confirm the immunological distinctions between the two types of OMVs, which could be attributed to differences in protein abundance, as indicated by proteomic analysis, or to variations in the exposure or accessibility of certain antigenic epitopes within the structure of &#916;<italic toggle="yes">mapB</italic> OMVs. The MapB homolog, TamB, has been implicated in maintaining cell envelope homeostasis, as demonstrated in our previous work (<xref rid="B36" ref-type="bibr">36</xref>) and in other bacterial genera (<xref rid="B56" ref-type="bibr">56</xref>&#8211;<xref rid="B58" ref-type="bibr">58</xref>). As a member of the AsmA protein family, TamB has been proposed to mediate the transport of phospholipids from the inner membrane (IM) to the OM in diderm bacteria. Supporting this, studies in <italic toggle="yes">E. coli</italic> have shown differential phospholipid composition between the IM and OM (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B59" ref-type="bibr">59</xref>). A membrane with altered lipid composition may affect its organization and fluidity, subsequently modifying the accessibility of surface antigens. These changes could explain the increased immunogenicity observed in OMVs derived from the &#916;<italic toggle="yes">mapB</italic> mutant strain. Further research will be required to confirm the contribution of MapB to the phospholipid composition of <italic toggle="yes">Brucella</italic> membranes and to better understand how these changes influence the immunogenicity and structural properties of OMVs from the mutant strain.</p><p>Importantly, serum from both the wt and &#916;<italic toggle="yes">mapB</italic> OMVs groups was able to neutralize bacterial adhesion and invasion of lung epithelial cells, and both mediated opsonophagocytosis by macrophages. Interestingly, immunization with &#916;<italic toggle="yes">mapB</italic> OMVs elicited a slight increase in specific IgA levels in saliva and BALF, suggesting that parenteral immunization with these vesicles may promote a limited but specific mucosal immune response.</p><p>In our study, OMVs from <italic toggle="yes">B. suis</italic> strains conferred protection against i.p. <italic toggle="yes">B. suis</italic> infection. This result is consistent with previous studies conducted by Avila Calderon et&#160;al. (<xref rid="B25" ref-type="bibr">25</xref>) and Araiza Villanueva et&#160;al. (<xref rid="B26" ref-type="bibr">26</xref>), which demonstrated that OMVs from <italic toggle="yes">B. melitensis</italic> and <italic toggle="yes">B. abortus</italic> confer comparable protection to vaccine strains against parenteral challenge with <italic toggle="yes">B. melitensis</italic> and <italic toggle="yes">B. abortus</italic>, respectively. Interestingly, immunization with &#916;<italic toggle="yes">mapB</italic> OMVs achieved higher levels of protection compared to immunization with wt OMVs, suggesting that the enhanced protective effect is linked to the more robust immune response elicited by &#916;<italic toggle="yes">mapB</italic> OMVs.</p><p>Since <italic toggle="yes">Brucella</italic> primarily invades hosts through the mucosal routes, the development of a vaccine capable of inducing a protective mucosal response is highly desirable. Although it is widely recognized that parenteral immunization typically fails to generate protective mucosal immune responses, recent studies have revealed that OMVs derived from <italic toggle="yes">Bordetella pertussis</italic> and <italic toggle="yes">Bordetella parapertussis</italic> can effectively protect against mucosal infection even when administered through non-mucosal routes (<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B60" ref-type="bibr">60</xref>). Notably, i.m. vaccination with wt OMVs and &#916;<italic toggle="yes">mapB</italic> OMVs provided partial protection against respiratory challenge with <italic toggle="yes">B. suis</italic>, leading to reduced splenic and lung CFU counts. To the best of our knowledge, this study represents the first evidence that an acellular vaccine based on OMVs from <italic toggle="yes">Brucella</italic> can confer partial protection against mucosal challenge.</p><p>While antibodies targeting the O-antigen of LPS can provide some degree of protection in certain host species, the primary defense against virulent <italic toggle="yes">Brucella</italic> infection relies on cell-mediated immunity (<xref rid="B61" ref-type="bibr">61</xref>). Since <italic toggle="yes">Brucella</italic> species are facultative intracellular pathogens that reside primarily in macrophages, cellular immune responses involving IFN-&#947;-producing CD4+ T cells are considered critical for protective immunity (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>). IFN-&#947; is often the most essential effector cytokine for activating macrophages, enhancing their ability to eliminate and inhibit replication of intracellular microbial pathogens (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>).</p><p>In the present work, we demonstrate that immunization with wt or &#916;<italic toggle="yes">mapB</italic> OMVs induces specific T cells capable of secreting high levels of IFN-&#947; and moderate levels of IL-17 in response to antigen stimulation. In particular, immunization with OMVs &#916;<italic toggle="yes">mapB</italic> produced higher levels of IFN-&#947; than immunization with wt OMVs, which may explain the higher levels of protection against systemic infection conferred by vaccination with vesicles from the mutant strain. Interestingly, Hanot Mambres et&#160;al. (<xref rid="B62" ref-type="bibr">62</xref>) demonstrated that the nature of the protective memory response is closely dependent on the pathway of <italic toggle="yes">Brucella</italic> infection and highlighted the necessity of IFN-&#947; and IL-17RA for controlling mucosal infection by <italic toggle="yes">Brucella melitensis</italic> (<xref rid="B62" ref-type="bibr">62</xref>). This background may explain the protection conferred by vaccination with both OMVs against mucosal challenge with <italic toggle="yes">B. suis</italic>. Nevertheless, further studies are needed to characterize the profile of antigen-specific T cells induced by OMV vaccination at mucosal sites. As depicted in <xref rid="f8" ref-type="fig">
<bold>Figure&#160;8</bold>
</xref>, immunization with &#916;<italic toggle="yes">mapB</italic> OMVs induced both mucosal and systemic immune responses, as evidenced by the production of anti-OMV IgG and IgA, as well as the activation of Th1 and Th17 cells, marked by IFN-&#947; and IL-17 secretion, respectively.</p><fig position="float" id="f8" orientation="portrait"><label>Figure&#160;8</label><caption><p>Model of the immune response elicited by &#916;<italic toggle="yes">mapB</italic> OMVs from <italic toggle="yes">Brucella suis</italic> as an immunogen. This model illustrates the immune response induced by OMVs derived from a <italic toggle="yes">Brucella suis</italic> &#916;<italic toggle="yes">mapB</italic> mutant. The OMVs, are spherical with a hydrodynamic diameter (D<sub>h</sub>) ranging from 105 to 119 nm. These OMVs contain key immunomodulatory components including LPS, phospholipids (PLs), and immunogenic proteins (BLS, Omp16, Omp19, Omp31, Omp25, SOD, GroEL, bacterioferritin, and SurA, among others), and act as a self-adjuvanting immunogen. Upon immunization in a murine model, OMVs trigger the production of anti-OMVs IgG in serum and anti-OMVs IgA in saliva and bronchoalveolar lavage fluid (BALF). Additionally, splenic cells from immunized mice were stimulated, leading to a Th1 immune response characterized by IFN-&#947; production and a Th17 response marked by IL-17 secretion.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-15-1501791-g008.jpg"/></fig><p>In this study, immunization with OMVs from both <italic toggle="yes">B. suis</italic> strains provided a protective immune response against virulent <italic toggle="yes">B. suis</italic> infection at both mucosal and systemic levels. However, we propose the use of &#916;<italic toggle="yes">mapB</italic> OMVs as a preferred vaccine candidate for the following reasons: 1) immunization with these OMVs showed superior protective efficacy, compared to wt OMVs in a parenteral challenge, 2) immunization with &#916;<italic toggle="yes">mapB</italic> OMVs induced a more robust humoral and cellular immune response compared to immunization with wt OMVs, and 3) the attenuated phenotype of the mutant strain improves the safety profile of the vaccine production process.</p><p>Overall, our study is the first to demonstrate <italic toggle="yes">B. suis</italic> OMVs immunogenicity and protective efficacy conferred against both systemic and respiratory challenges by virulent <italic toggle="yes">B. suis</italic>.</p><p>This work provides an assessment of the immunogenicity and protective efficacy of <italic toggle="yes">B. suis</italic> OMVs in a murine model. Further studies are needed to determine the long-term immunity and effectiveness of OMVs as vaccines in the natural host.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank Sebasti&#225;n Elena, Ana Mar&#237;a Nicola and Cristina Franco from Brucellosis Department, DILAB, Servicio Nacional de Sanidad y Calidad Agroalimentaria (SENASA) for providing porcine sera.</p></ack><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The original contributions presented in the study are included in the article/<xref rid="SM1" ref-type="supplementary-material">
<bold>Supplementary Material</bold>
</xref>, further inquiries can be directed to the corresponding authors.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. The animal study was approved by Institutional Committee for the Care and Use of Laboratory Animals-Faculty of Pharmacy and Biochemistry, University of Buenos Aires. The study was conducted in accordance with the local legislation and institutional requirements.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>FG: Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Writing &#8211; original draft, Writing &#8211; review &amp; editing. MB: Conceptualization, Data curation, Investigation, Methodology, Validation, Writing &#8211; original draft, Writing &#8211; review &amp; editing, Funding acquisition. MC: Data curation, Investigation, Methodology, Writing &#8211; original draft. SE: Data curation, Investigation, Methodology, Writing &#8211; original draft. LR: Investigation, Methodology, Writing &#8211; original draft. PB: Data curation, Supervision, Writing &#8211; original draft, Writing &#8211; review &amp; editing. &#193;Z: Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Supervision, Writing &#8211; original draft, Writing &#8211; review &amp; editing. MF: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing &#8211; original draft, Writing &#8211; review &amp; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="s12"><title>Supplementary material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2024.1501791/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1501791/full#supplementary-material</ext-link>
</p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="DataSheet1.pdf" position="float" orientation="portrait"/></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappas</surname><given-names>G</given-names></name><name name-style="western"><surname>Akritidis</surname><given-names>N</given-names></name><name name-style="western"><surname>Bosilkovski</surname><given-names>M</given-names></name><name name-style="western"><surname>Tsianos</surname><given-names>E</given-names></name></person-group>. <article-title>Brucellosis</article-title>. <source>N Engl J Med</source>. (<year>2005</year>) <volume>352</volume>:<page-range>2325&#8211;36</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1056/NEJMra050570</pub-id><pub-id pub-id-type="pmid">15930423</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>G</given-names></name><name name-style="western"><surname>Osterman</surname><given-names>BS</given-names></name><name name-style="western"><surname>Godfroid</surname><given-names>J</given-names></name><name name-style="western"><surname>Jacques</surname><given-names>I</given-names></name><name name-style="western"><surname>Cloeckert</surname><given-names>A</given-names></name></person-group>. <article-title>
<italic toggle="yes">Brucella ceti</italic> sp. nov. and <italic toggle="yes">Brucella pinnipedialis</italic> sp. nov. for <italic toggle="yes">Brucella</italic> strains with cetaceans and seals as their preferred hosts</article-title>. <source>Int J Syst Evol Microbiol</source>. (<year>2007</year>) <volume>57</volume>:<page-range>2688&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1099/ijs.0.65269-0</pub-id><pub-id pub-id-type="pmid">17978241</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Godfroid</surname><given-names>J</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>HC</given-names></name><name name-style="western"><surname>Barbier</surname><given-names>T</given-names></name><name name-style="western"><surname>Nicolas</surname><given-names>C</given-names></name><name name-style="western"><surname>Wattiau</surname><given-names>P</given-names></name><name name-style="western"><surname>Fretin</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Brucellosis at the animal/ecosystem/human interface at the beginning of the 21st century</article-title>. <source>Prev Vet Med</source>. (<year>2011</year>) <volume>102</volume>:<page-range>118&#8211;31</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.prevetmed.2011.04.007</pub-id><pub-id pub-id-type="pmid">21571380</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholz</surname><given-names>HC</given-names></name><name name-style="western"><surname>Hubalek</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sedl&#225;&#269;ek</surname><given-names>I</given-names></name><name name-style="western"><surname>Vergnaud</surname><given-names>G</given-names></name><name name-style="western"><surname>Tomaso</surname><given-names>H</given-names></name><name name-style="western"><surname>Al Dahouk</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>
<italic toggle="yes">Brucella microti</italic> sp. nov., isolated from the common vole <italic toggle="yes">Microtus arvalis</italic>
</article-title>. <source>Int J Syst Evol Microbiol</source>. (<year>2008</year>) <volume>58</volume>:<page-range>375&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1099/ijs.0.65356-0</pub-id><pub-id pub-id-type="pmid">18218934</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scholz</surname><given-names>HC</given-names></name><name name-style="western"><surname>Revilla-Fern&#225;ndez</surname><given-names>S</given-names></name><name name-style="western"><surname>Dahouk</surname><given-names>S</given-names></name><name name-style="western"><surname>Hammerl</surname><given-names>JA</given-names></name><name name-style="western"><surname>Zygmunt</surname><given-names>MS</given-names></name><name name-style="western"><surname>Cloeckaert</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>
<italic toggle="yes">Brucella vulpis</italic> sp. Nov., isolated from mandibular lymph nodes of red foxes (vulpes vulpes)</article-title>. <source>Int J Syst Evol Microbiol</source>. (<year>2016</year>) <volume>66</volume>:<page-range>2090&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1099/ijsem.0.000998</pub-id><pub-id pub-id-type="pmid">26928956</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olsen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Tatum</surname><given-names>FM</given-names></name></person-group>. <article-title>Swine brucellosis: current perspectives</article-title>. <source>Vet Med (Auckl)</source>. (<year>2016</year>) <volume>8</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.2147/VMRR.S91360</pub-id><pub-id pub-id-type="pmid">30050849</pub-id><pub-id pub-id-type="pmcid">PMC6042558</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrero</surname><given-names>MC</given-names></name><name name-style="western"><surname>Alonso Paiva</surname><given-names>IM</given-names></name><name name-style="western"><surname>Mu&#241;oz Gonz&#225;lez</surname><given-names>F</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name></person-group>. <article-title>Pathogenesis and immune response in <italic toggle="yes">Brucella</italic> infection acquired by the respiratory route</article-title>. <source>Microbes Infect</source>. (<year>2020</year>) <volume>22</volume>:<page-range>407&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.micinf.2020.06.001</pub-id><pub-id pub-id-type="pmid">32535086</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seleem</surname><given-names>MN</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>SM</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name></person-group>. <article-title>Brucellosis: A re-emerging zoonosis</article-title>. <source>Vet Microbiol</source>. (<year>2010</year>) <volume>140</volume>:<page-range>392&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vetmic.2009.06.021</pub-id><pub-id pub-id-type="pmid">19604656</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallach</surname><given-names>JC</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>JL</given-names></name><name name-style="western"><surname>Cardinali</surname><given-names>PS</given-names></name><name name-style="western"><surname>Seijo</surname><given-names>AP</given-names></name><name name-style="western"><surname>Benchetrit</surname><given-names>AG</given-names></name><name name-style="western"><surname>Echazarreta</surname><given-names>SE</given-names></name><etal/></person-group>. <article-title>High incidence of respiratory involvement in a cluster of <italic toggle="yes">Brucella suis</italic>-infected workers from a pork processing plant in Argentina</article-title>. <source>Zoonoses Public Health</source>. (<year>2017</year>) <volume>64</volume>:<page-range>550&#8211;3</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/zph.12339</pub-id><pub-id pub-id-type="pmid">28032696</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashford</surname><given-names>DA</given-names></name><name name-style="western"><surname>Di Pietra</surname><given-names>J</given-names></name><name name-style="western"><surname>Lingappa</surname><given-names>J</given-names></name><name name-style="western"><surname>Woods</surname><given-names>C</given-names></name><name name-style="western"><surname>Noll</surname><given-names>H</given-names></name><name name-style="western"><surname>Neville</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51</article-title>. <source>Vaccine</source>. (<year>2004</year>) <volume>22</volume>:<page-range>3435&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2004.02.041</pub-id><pub-id pub-id-type="pmid">15308369</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallach</surname><given-names>JC</given-names></name><name name-style="western"><surname>Ferrero</surname><given-names>MC</given-names></name><name name-style="western"><surname>Victoria Delpino</surname><given-names>M</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name></person-group>. <article-title>Occupational infection due to <italic toggle="yes">Brucella abortus</italic> S19 among workers involved in vaccine production in Argentina</article-title>. <source>Clin Microbiol Infect</source>. (<year>2008</year>) <volume>14</volume>:<page-range>805&#8211;7</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/j.1469-0691.2008.02029.x</pub-id><pub-id pub-id-type="pmid">18727806</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blasco</surname><given-names>JM</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>R</given-names></name></person-group>. <article-title>
<italic toggle="yes">Brucella melitensis</italic> Rev-1 vaccine as a cause of human brucellosis</article-title>. <source>Lancet</source>. (<year>1993</year>) <volume>342</volume>:<fpage>805</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/0140-6736(93)91571-3</pub-id><pub-id pub-id-type="pmid">8103891</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwechheimer</surname><given-names>C</given-names></name><name name-style="western"><surname>Kuehn</surname><given-names>MJ</given-names></name></person-group>. <article-title>Outer-membrane vesicles from Gram-negative bacteria: Biogenesis and functions</article-title>. <source>Nat Rev Microbiol</source>. (<year>2015</year>) <volume>13</volume>:<page-range>605&#8211;19</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nrmicro3525</pub-id><pub-id pub-id-type="pmcid">PMC5308417</pub-id><pub-id pub-id-type="pmid">26373371</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dhital</surname><given-names>S</given-names></name><name name-style="western"><surname>Deo</surname><given-names>P</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>I</given-names></name><name name-style="western"><surname>Naderer</surname><given-names>T</given-names></name></person-group>. <article-title>Bacterial outer membrane vesicles and host cell death signaling</article-title>. <source>Trends Microbiol</source>. (<year>2021</year>) <volume>29</volume>:<page-range>1106&#8211;16</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.tim.2021.04.003</pub-id><pub-id pub-id-type="pmid">34001418</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerrero-Mandujano</surname><given-names>A</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Cortez</surname><given-names>C</given-names></name><name name-style="western"><surname>Ibarra</surname><given-names>JA</given-names></name><name name-style="western"><surname>Castro-Escarpulli</surname><given-names>G</given-names></name></person-group>. <article-title>The outer membrane vesicles: Secretion system type zero</article-title>. <source>Traffic</source>. (<year>2017</year>) <volume>18</volume>:<page-range>425&#8211;32</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/tra.12488</pub-id><pub-id pub-id-type="pmid">28421662</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>TN</given-names></name><name name-style="western"><surname>Leiman</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kuehn</surname><given-names>MJ</given-names></name></person-group>. <article-title>Naturally produced outer membrane vesicles from <italic toggle="yes">Pseudomonas aeruginosa</italic> elicit a potent innate immune response via combined sensing of both lipopolysaccharide and protein components</article-title>. <source>Infect Immun</source>. (<year>2010</year>) <volume>78</volume>:<page-range>3822&#8211;31</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.00433-10</pub-id><pub-id pub-id-type="pmcid">PMC2937433</pub-id><pub-id pub-id-type="pmid">20605984</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schild</surname><given-names>S</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Camilli</surname><given-names>A</given-names></name></person-group>. <article-title>Immunization with <italic toggle="yes">Vibrio cholerae</italic> outer membrane vesicles induces protective immunity in mice</article-title>. <source>Infect Immun</source>. (<year>2008</year>) <volume>76</volume>:<page-range>4554&#8211;63</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.00532-08</pub-id><pub-id pub-id-type="pmcid">PMC2546833</pub-id><pub-id pub-id-type="pmid">18678672</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alaniz</surname><given-names>RC</given-names></name><name name-style="western"><surname>Deatherage</surname><given-names>BL</given-names></name><name name-style="western"><surname>Lara</surname><given-names>JC</given-names></name><name name-style="western"><surname>Cookson</surname><given-names>BT</given-names></name></person-group>. <article-title>Membrane vesicles are immunogenic facsimiles of <italic toggle="yes">Salmonella typhimurium</italic> that potently activate dendritic cells, prime B and T cell responses, and stimulate protective immunity <italic toggle="yes">in vivo</italic> [published correction appears in <italic toggle="yes">J Immunol.</italic> 2008 Mar 1;180(5):3612</article-title>. <source>J Immunol</source>. (<year>2007</year>) <volume>179</volume>:<page-range>7692&#8211;701</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.179.11.7692</pub-id><pub-id pub-id-type="pmid">18025215</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Camacho</surname><given-names>AI</given-names></name><name name-style="western"><surname>De Souza</surname><given-names>J</given-names></name><name name-style="western"><surname>S&#225;nchez-G&#243;mez</surname><given-names>S</given-names></name><name name-style="western"><surname>Pardo-Ros</surname><given-names>M</given-names></name><name name-style="western"><surname>Irache</surname><given-names>JM</given-names></name><name name-style="western"><surname>Gamazo</surname><given-names>C</given-names></name></person-group>. <article-title>Mucosal immunization with <italic toggle="yes">Shigella flexneri</italic> outer membrane vesicles induced protection in mice</article-title>. <source>Vaccine</source>. (<year>2011</year>) <volume>29</volume>:<page-range>8222&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.08.121</pub-id><pub-id pub-id-type="pmid">21911022</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asensio</surname><given-names>CJA</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>ME</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>G</given-names></name><name name-style="western"><surname>Bottero</surname><given-names>D</given-names></name><name name-style="western"><surname>Zurita</surname><given-names>E</given-names></name><name name-style="western"><surname>Rumbo</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Outer membrane vesicles obtained from <italic toggle="yes">Bordetella pertussis Tohama</italic> expressing the lipid a deacylase PagL as a novel acellular vaccine candidate</article-title>. <source>Vaccine</source>. (<year>2011</year>) <volume>29</volume>:<page-range>1649&#8211;56</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.068</pub-id><pub-id pub-id-type="pmid">21211579</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bottero</surname><given-names>D</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>ME</given-names></name><name name-style="western"><surname>Errea</surname><given-names>A</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>G</given-names></name><name name-style="western"><surname>Zurita</surname><given-names>E</given-names></name><name name-style="western"><surname>Pianciola</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Outer membrane vesicles derived from <italic toggle="yes">Bordetella parapertussis</italic> as an acellular vaccine against <italic toggle="yes">Bordetella parapertussis</italic> and <italic toggle="yes">Bordetella pertussis</italic> infection</article-title>. <source>Vaccine</source>. (<year>2013</year>) <volume>31</volume>:<page-range>5262&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2013.08.059</pub-id><pub-id pub-id-type="pmid">24012570</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raeven</surname><given-names>RHM</given-names></name><name name-style="western"><surname>Rockx-Brouwer</surname><given-names>D</given-names></name><name name-style="western"><surname>Kanojia</surname><given-names>G</given-names></name><name name-style="western"><surname>van der Maas</surname><given-names>L</given-names></name><name name-style="western"><surname>Bindels</surname><given-names>THE</given-names></name><name name-style="western"><surname>ten Have</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Intranasal immunization with outer membrane vesicle pertussis vaccine confers broad protection through mucosal IgA and Th17 responses</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>7396</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-020-63998-2</pub-id><pub-id pub-id-type="pmid">32355188</pub-id><pub-id pub-id-type="pmcid">PMC7192948</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Ley</surname><given-names>PA</given-names></name><name name-style="western"><surname>Zariri</surname><given-names>A</given-names></name><name name-style="western"><surname>van Riet</surname><given-names>E</given-names></name><name name-style="western"><surname>Oosterhoff</surname><given-names>D</given-names></name><name name-style="western"><surname>Kruiswijk</surname><given-names>CP</given-names></name></person-group>. <article-title>An Intranasal OMV-based vaccine induces high mucosal and systemic protecting immunity against a SARS-CoV-2 infection</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>781280</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2021.781280</pub-id><pub-id pub-id-type="pmid">34987509</pub-id><pub-id pub-id-type="pmcid">PMC8721663</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holst</surname><given-names>J</given-names></name><name name-style="western"><surname>Oster</surname><given-names>P</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>R</given-names></name><name name-style="western"><surname>Tatley</surname><given-names>MV</given-names></name><name name-style="western"><surname>N&#230;ss</surname><given-names>LM</given-names></name><name name-style="western"><surname>Aaberge</surname><given-names>IS</given-names></name><etal/></person-group>. <article-title>Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV) Lessons from past programs and implications for the future</article-title>. <source>Hum Vaccin Immunother</source>. (<year>2013</year>) <volume>9</volume>:<page-range>1241&#8211;53</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4161/hv.24129</pub-id><pub-id pub-id-type="pmcid">PMC3901813</pub-id><pub-id pub-id-type="pmid">23857274</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avila-Calder&#243;n</surname><given-names>ED</given-names></name><name name-style="western"><surname>Lopez-Merino</surname><given-names>A</given-names></name><name name-style="western"><surname>Jain</surname><given-names>N</given-names></name><name name-style="western"><surname>Peralta</surname><given-names>H</given-names></name><name name-style="western"><surname>Lopez-Villegas</surname><given-names>EO</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Characterization of outer membrane vesicles from <italic toggle="yes">Brucella melitensis</italic> and protection induced in mice</article-title>. <source>Clin Dev Immunol</source>. (<year>2012</year>) <volume>2012</volume>:<elocation-id>352493</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1155/2012/352493</pub-id><pub-id pub-id-type="pmid">22242036</pub-id><pub-id pub-id-type="pmcid">PMC3254011</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araiza-Villanueva</surname><given-names>M</given-names></name><name name-style="western"><surname>Avila-Calder&#243;n</surname><given-names>ED</given-names></name><name name-style="western"><surname>Flores-Romo</surname><given-names>L</given-names></name><name name-style="western"><surname>Calder&#243;n-Amador</surname><given-names>J</given-names></name><name name-style="western"><surname>Sriranganathan</surname><given-names>N</given-names></name><name name-style="western"><surname>Al</surname><given-names>QH</given-names></name><etal/></person-group>. <article-title>Proteomic analysis of membrane blebs of <italic toggle="yes">Brucella abortus</italic> 2308 and RB51 and their evaluation as an acellular vaccine</article-title>. <source>Front Microbiol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>2714</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2019.02714</pub-id><pub-id pub-id-type="pmid">31849872</pub-id><pub-id pub-id-type="pmcid">PMC6895012</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Socorro Ruiz-Palma</surname><given-names>Md</given-names></name><name name-style="western"><surname>Avila-Calder&#243;n</surname><given-names>ED</given-names></name><name name-style="western"><surname>Aguilera-Arreola</surname><given-names>MG</given-names></name><name name-style="western"><surname>L&#243;pez-Merino</surname><given-names>A</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>EA</given-names></name><name name-style="western"><surname>Morales-Garc&#237;a M del</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Comparative proteomic analysis of outer membrane vesicles from <italic toggle="yes">Brucella suis, Brucella ovis, Brucella canis</italic> and <italic toggle="yes">Brucella neotomae</italic>
</article-title>. <source>Arch Microbiol</source>. (<year>2021</year>) <volume>203</volume>:<page-range>1611&#8211;26</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00203-020-02170-w</pub-id><pub-id pub-id-type="pmcid">PMC7799404</pub-id><pub-id pub-id-type="pmid">33432377</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Samartino</surname><given-names>CG</given-names></name><name name-style="western"><surname>Zwerdling</surname><given-names>A</given-names></name><name name-style="western"><surname>Coria</surname><given-names>LM</given-names></name><name name-style="western"><surname>Barrionuevo</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Immunization with recombinant <italic toggle="yes">Brucella</italic> species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against <italic toggle="yes">Brucella abortus</italic> infection</article-title>. <source>Infect Immun</source>. (<year>2009</year>) <volume>77</volume>:<page-range>436&#8211;45</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.01151-08</pub-id><pub-id pub-id-type="pmcid">PMC2612246</pub-id><pub-id pub-id-type="pmid">18981242</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pasquevich</surname><given-names>KA</given-names></name><name name-style="western"><surname>Garc&#237;a Samartino</surname><given-names>C</given-names></name><name name-style="western"><surname>Coria</surname><given-names>LM</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Zwerdling</surname><given-names>A</given-names></name><name name-style="western"><surname>Iba&#241;ez</surname><given-names>AE</given-names></name><etal/></person-group>. <article-title>The protein moiety of <italic toggle="yes">Brucella abortus</italic> outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells <italic toggle="yes">in vivo</italic>, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired Brucellosis</article-title>. <source>J Immunol</source>. (<year>2010</year>) <volume>184</volume>:<page-range>5200&#8211;12</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.0902209</pub-id><pub-id pub-id-type="pmid">20351187</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jubier-Maurin</surname><given-names>V</given-names></name><name name-style="western"><surname>Boigegrain</surname><given-names>RA</given-names></name><name name-style="western"><surname>Cloeckaert</surname><given-names>A</given-names></name><name name-style="western"><surname>Gross</surname><given-names>A</given-names></name><name name-style="western"><surname>Alvarez-Martinez</surname><given-names>MT</given-names></name><name name-style="western"><surname>Terraza</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Major outer membrane protein Omp25 of <italic toggle="yes">Brucella suis</italic> is involved in inhibition of tumor necrosis factor alpha production during infection of human macrophages</article-title>. <source>Infect Immun</source>. (<year>2001</year>) <volume>69</volume>:<page-range>4823&#8211;30</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.69.8.4823-4830.2001</pub-id><pub-id pub-id-type="pmcid">PMC98570</pub-id><pub-id pub-id-type="pmid">11447156</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name><name name-style="western"><surname>Velikovsky</surname><given-names>CA</given-names></name><name name-style="western"><surname>Bruno</surname><given-names>L</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>de la Barrera</surname><given-names>S</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding <italic toggle="yes">Brucella melitensis</italic> outer membrane protein 31 (Omp31) and recombinant Omp31 boosting</article-title>. <source>Clin Vaccine Immunol</source>. (<year>2007</year>) <volume>14</volume>:<page-range>869&#8211;74</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/CVI.00472-06</pub-id><pub-id pub-id-type="pmcid">PMC1951060</pub-id><pub-id pub-id-type="pmid">17428946</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abkar</surname><given-names>M</given-names></name><name name-style="western"><surname>Alamian</surname><given-names>S</given-names></name><name name-style="western"><surname>Sattarahmady</surname><given-names>N</given-names></name></person-group>. <article-title>A comparison between adjuvant and delivering functions of calcium phosphate, aluminum hydroxide and chitosan nanoparticles, using a model protein of <italic toggle="yes">Brucella melitensis</italic> Omp31</article-title>. <source>Immunol Lett</source>. (<year>2019</year>) <volume>207</volume>:<fpage>28</fpage>&#8211;<lpage>35</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.imlet.2019.01.010</pub-id><pub-id pub-id-type="pmid">30707922</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selkrig</surname><given-names>J</given-names></name><name name-style="western"><surname>Mosbahi</surname><given-names>K</given-names></name><name name-style="western"><surname>Webb</surname><given-names>CT</given-names></name><name name-style="western"><surname>Belousoff</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Perry</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Wells</surname><given-names>TJ</given-names></name><etal/></person-group>. <article-title>Discovery of an archetypal protein transport system in bacterial outer membranes</article-title>. <source>Nat Struct Mol Biol</source>. (<year>2012</year>) <volume>19</volume>:<page-range>506&#8211;10</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/nsmb.2261</pub-id><pub-id pub-id-type="pmid">22466966</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz</surname><given-names>N</given-names></name><name name-style="western"><surname>Davis</surname><given-names>RM</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S</given-names></name></person-group>. <article-title>YhdP, TamB, and YdbH Are Redundant but essential for growth and lipid homeostasis of the Gram-negative outer membrane</article-title>. <source>mBio</source>. (<year>2021</year>) <volume>12</volume>:<fpage>e0271421</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/mBio.02714-21</pub-id><pub-id pub-id-type="pmid">34781743</pub-id><pub-id pub-id-type="pmcid">PMC8593681</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goh</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Stubenrauch</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Lithgow</surname><given-names>T</given-names></name></person-group>. <article-title>The TAM, a translocation and assembly module for protein assembly and potential conduit for phospholipid transfer</article-title>. <source>EMBO Rep</source>. (<year>2024</year>) <volume>25</volume>:<page-range>1711&#8211;20</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s44319-024-00111-y</pub-id><pub-id pub-id-type="pmcid">PMC11014939</pub-id><pub-id pub-id-type="pmid">38467907</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bialer</surname><given-names>MG</given-names></name><name name-style="western"><surname>Ruiz-Ranwez</surname><given-names>V</given-names></name><name name-style="western"><surname>Sycz</surname><given-names>G</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Russo</surname><given-names>DM</given-names></name><name name-style="western"><surname>Altabe</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>MapB, the <italic toggle="yes">Brucella suis</italic> TamB homologue, is involved in cell envelope biogenesis, cell division and virulence</article-title>. <source>Sci Rep</source>. (<year>2019</year>) <volume>9</volume>:<fpage>2158</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/s41598-018-37668-3</pub-id><pub-id pub-id-type="pmid">30770847</pub-id><pub-id pub-id-type="pmcid">PMC6377625</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name><name name-style="western"><surname>Fei</surname><given-names>X</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>G</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>The role of TolA, TolB, and TolR in cell morphology, OMVs production, and virulence of <italic toggle="yes">Salmonella Choleraesuis</italic>
</article-title>. <source>AMB Express</source>. (<year>2022</year>) <volume>25;12</volume>:<elocation-id>5</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1186/s13568-022-01347-4</pub-id><pub-id pub-id-type="pmcid">PMC8787014</pub-id><pub-id pub-id-type="pmid">35075554</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitra</surname><given-names>S</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>R</given-names></name><name name-style="western"><surname>Mitobe</surname><given-names>J</given-names></name><name name-style="western"><surname>Koley</surname><given-names>H</given-names></name></person-group>. <article-title>Development of a cost-effective vaccine candidate with outer membrane vesicles of a tolA-disrupted <italic toggle="yes">Shigella boydii</italic> strain</article-title>. <source>Vaccine</source>. (<year>2016</year>) <volume>34</volume>:<page-range>1839&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2016.02.018</pub-id><pub-id pub-id-type="pmid">26878295</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moon</surname><given-names>DC</given-names></name><name name-style="western"><surname>Choi</surname><given-names>CH</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><name name-style="western"><surname>Choi</surname><given-names>CW</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HY</given-names></name><name name-style="western"><surname>Park</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>
<italic toggle="yes">Acinetobacter baumannii</italic> outer membrane protein A modulates the biogenesis of outer membrane vesicles</article-title>. <source>J Microbiol</source>. (<year>2012</year>) <volume>50</volume>:<page-range>155&#8211;60</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s12275-012-1589-4</pub-id><pub-id pub-id-type="pmid">22367951</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>L</given-names></name><name name-style="western"><surname>Praszkier</surname><given-names>J</given-names></name><name name-style="western"><surname>Hutton</surname><given-names>ML</given-names></name><name name-style="western"><surname>Steer</surname><given-names>D</given-names></name><name name-style="western"><surname>Ramm</surname><given-names>G</given-names></name><name name-style="western"><surname>Kaparakis-Liaskos</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Increased Outer Membrane Vesicle Formation in a <italic toggle="yes">Helicobacter pylori</italic> tolB Mutant</article-title>. <source>Helicobacter</source>. (<year>2015</year>) <volume>20</volume>:<page-range>269&#8211;83</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1111/hel.12196</pub-id><pub-id pub-id-type="pmid">25669590</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollak</surname><given-names>CN</given-names></name><name name-style="western"><surname>Delpino</surname><given-names>MV</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name></person-group>. <article-title>Outer membrane vesicles from <italic toggle="yes">Brucella abortus</italic> promote bacterial internalization by human monocytes and modulate their innate immune response</article-title>. <source>PloS One</source>. (<year>2012</year>) <volume>7</volume>:<fpage>e50214</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0050214</pub-id><pub-id pub-id-type="pmid">23189190</pub-id><pub-id pub-id-type="pmcid">PMC3506553</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruiz-Ranwez</surname><given-names>V</given-names></name><name name-style="western"><surname>Posadas</surname><given-names>DM</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Abdian</surname><given-names>PL</given-names></name><name name-style="western"><surname>Martin</surname><given-names>FA</given-names></name><name name-style="western"><surname>Zorreguieta</surname><given-names>A</given-names></name></person-group>. <article-title>The BtaF trimeric autotransporter of <italic toggle="yes">Brucella suis is</italic> involved in attachment to various surfaces, resistance to serum and virulence</article-title>. <source>PloS One</source>. (<year>2013</year>) <volume>13;8</volume>:<fpage>e79770</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0079770</pub-id><pub-id pub-id-type="pmcid">PMC3827427</pub-id><pub-id pub-id-type="pmid">24236157</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Foster</surname><given-names>CN</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>UA</given-names></name><name name-style="western"><surname>Zubieta</surname><given-names>MRC</given-names></name><name name-style="western"><surname>Vanzini</surname><given-names>V</given-names></name><name name-style="western"><surname>Rossetti</surname><given-names>CA</given-names></name></person-group>. <article-title>Evaluation of <italic toggle="yes">B. melitensis</italic> whole-cell lysate antigen-based indirect ELISA for the serodiagnosis of caprine brucellosis</article-title>. <source>Res Vet Sci</source>. (<year>2022</year>) <volume>147</volume>:<fpage>1</fpage>&#8211;<lpage>6</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.rvsc.2022.03.015</pub-id><pub-id pub-id-type="pmid">35334432</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu&#241;oz Gonz&#225;lez</surname><given-names>F</given-names></name><name name-style="western"><surname>Sycz</surname><given-names>G</given-names></name><name name-style="western"><surname>Alonso Paiva</surname><given-names>IM</given-names></name><name name-style="western"><surname>Linke</surname><given-names>D</given-names></name><name name-style="western"><surname>Zorreguieta</surname><given-names>A</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name><etal/></person-group>. <article-title>The BtaF adhesin is necessary for full virulence during respiratory infection by <italic toggle="yes">Brucella suis</italic> and is a novel immunogen for nasal vaccination against <italic toggle="yes">Brucella</italic> infection</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>1775</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.01775</pub-id><pub-id pub-id-type="pmid">31402921</pub-id><pub-id pub-id-type="pmcid">PMC6676368</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delpino</surname><given-names>MV</given-names></name><name name-style="western"><surname>Estein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Fossati</surname><given-names>CA</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>PC</given-names></name><name name-style="western"><surname>Cassataro</surname><given-names>J</given-names></name></person-group>. <article-title>Vaccination with <italic toggle="yes">Brucella</italic> recombinant DnaK and SurA proteins induces protection against <italic toggle="yes">Brucella abortus</italic> infection in BALB/c mice</article-title>. <source>Vaccine</source>. (<year>2007</year>) <volume>25</volume>:<page-range>6721&#8211;9</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2007.07.002</pub-id><pub-id pub-id-type="pmid">17686554</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zriba</surname><given-names>S</given-names></name><name name-style="western"><surname>Garcia-Gonzalez</surname><given-names>DG</given-names></name><name name-style="western"><surname>Khalaf</surname><given-names>OH</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>L</given-names></name><name name-style="western"><surname>Chaki</surname><given-names>SP</given-names></name><name name-style="western"><surname>Rice-Ficht</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Vaccine safety studies of <italic toggle="yes">Brucella abortus</italic> S19 and S19&#916;<italic toggle="yes">vjbR</italic> in pregnant swine</article-title>. <source>Vaccine X</source>. (<year>2019</year>) <volume>3</volume>:<elocation-id>100041</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jvacx.2019.100041</pub-id><pub-id pub-id-type="pmid">31528851</pub-id><pub-id pub-id-type="pmcid">PMC6737346</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tibor</surname><given-names>A</given-names></name><name name-style="western"><surname>Wansard</surname><given-names>V</given-names></name><name name-style="western"><surname>Bielartz</surname><given-names>V</given-names></name><name name-style="western"><surname>Delrue</surname><given-names>RM</given-names></name><name name-style="western"><surname>Danese</surname><given-names>I</given-names></name><name name-style="western"><surname>Michel</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Effect of omp10 or omp19 deletion on <italic toggle="yes">Brucella abortus</italic> outer membrane properties and virulence in mice</article-title>. <source>Infect Immun</source>. (<year>2002</year>) <volume>70</volume>:<page-range>5540&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.70.10.5540-5546.2002</pub-id><pub-id pub-id-type="pmcid">PMC128365</pub-id><pub-id pub-id-type="pmid">12228280</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paulsson</surname><given-names>M</given-names></name><name name-style="western"><surname>Kragh</surname><given-names>KN</given-names></name><name name-style="western"><surname>Su</surname><given-names>YC</given-names></name><name name-style="western"><surname>Sandblad</surname><given-names>L</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B</given-names></name><name name-style="western"><surname>Bjarnsholt</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Peptidoglycan-binding anchor is a <italic toggle="yes">Pseudomonas aeruginosa</italic> OmpA family lipoprotein with importance for outer membrane vesicles, biofilms, and the periplasmic shape</article-title>. <source>Front Microbiol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>639582</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fmicb.2021.639582</pub-id><pub-id pub-id-type="pmid">33717034</pub-id><pub-id pub-id-type="pmcid">PMC7947798</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rouvi&#232;re</surname><given-names>PE</given-names></name><name name-style="western"><surname>Gross</surname><given-names>CA</given-names></name></person-group>. <article-title>SurA, a periplasmic protein with peptidyl-prolyl isomerase activity, participates in the assembly of outer membrane porins</article-title>. <source>Genes Dev</source>. (<year>1996</year>) <volume>10</volume>:<page-range>3170&#8211;82</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1101/gad.10.24.3170</pub-id><pub-id pub-id-type="pmid">8985185</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figaj</surname><given-names>D</given-names></name><name name-style="western"><surname>Ambroziak</surname><given-names>P</given-names></name><name name-style="western"><surname>Rzepka</surname><given-names>I</given-names></name><name name-style="western"><surname>Sk&#243;rko-Glonek</surname><given-names>J</given-names></name></person-group>. <article-title>SurA-like and Skp-like proteins as important virulence determinants of the gram negative bacterial pathogens</article-title>. <source>Int J Mol Sci</source>. (<year>2023</year>) <volume>24</volume>:<elocation-id>295</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3390/ijms24010295</pub-id><pub-id pub-id-type="pmcid">PMC9820271</pub-id><pub-id pub-id-type="pmid">36613738</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heidary</surname><given-names>M</given-names></name><name name-style="western"><surname>Dashtbin</surname><given-names>S</given-names></name><name name-style="western"><surname>Ghanavati</surname><given-names>R</given-names></name><name name-style="western"><surname>Mahdizade Ari</surname><given-names>M</given-names></name><name name-style="western"><surname>Bostanghadiri</surname><given-names>N</given-names></name><name name-style="western"><surname>Darbandi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Evaluation of brucellosis vaccines: A comprehensive review</article-title>. <source>Front Vet Sci</source>. (<year>2022</year>) <volume>9</volume>:<elocation-id>925773</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fvets.2022.925773</pub-id><pub-id pub-id-type="pmid">35923818</pub-id><pub-id pub-id-type="pmcid">PMC9339783</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boigegrain</surname><given-names>RA</given-names></name><name name-style="western"><surname>Salhi</surname><given-names>I</given-names></name><name name-style="western"><surname>Alvarez-Martinez</surname><given-names>MT</given-names></name><name name-style="western"><surname>Machold</surname><given-names>J</given-names></name><name name-style="western"><surname>Fedon</surname><given-names>Y</given-names></name><name name-style="western"><surname>Arpagaus</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Release of periplasmic proteins of <italic toggle="yes">Brucella suis</italic> upon acidic shock involves the outer membrane protein Omp25</article-title>. <source>Infect Immun</source>. (<year>2004</year>) <volume>72</volume>:<page-range>5693&#8211;703</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/IAI.72.10.5693-5703.2004</pub-id><pub-id pub-id-type="pmcid">PMC517528</pub-id><pub-id pub-id-type="pmid">15385468</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Han</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>
<italic toggle="yes">Brucella</italic> downregulates tumor necrosis factor-&#945; to promote intracellular survival via Omp25 regulation of different microRNAs in porcine and murine macrophages</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>8</volume>:<elocation-id>2013</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2017.02013</pub-id><pub-id pub-id-type="pmid">29387067</pub-id><pub-id pub-id-type="pmcid">PMC5776175</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verdiguel-Fern&#225;ndez</surname><given-names>L</given-names></name><name name-style="western"><surname>Oropeza-Navarro</surname><given-names>R</given-names></name><name name-style="western"><surname>Basurto-Alc&#225;ntara</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Casta&#241;eda-Ram&#237;rez</surname><given-names>A</given-names></name><name name-style="western"><surname>Verdugo-Rodr&#237;guez</surname><given-names>A</given-names></name></person-group>. <article-title>Omp31 plays an important role on outer membrane properties and intracellular survival of <italic toggle="yes">Brucella melitensis</italic> in murine macrophages and HeLa cells</article-title>. <source>Arch Microbiol</source>. (<year>2017</year>) <volume>199</volume>:<page-range>971&#8211;8</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1007/s00203-017-1360-7</pub-id><pub-id pub-id-type="pmid">28382472</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leclerq</surname><given-names>S</given-names></name><name name-style="western"><surname>Harms</surname><given-names>JS</given-names></name><name name-style="western"><surname>Rosinha</surname><given-names>GMS</given-names></name><name name-style="western"><surname>Azevedo</surname><given-names>V</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>SC</given-names></name></person-group>. <article-title>Induction of a th1-type of immune response but not protective immunity by intramuscular DNA immunisation with <italic toggle="yes">Brucella abortus</italic> GroEL heat-shock gene</article-title>. <source>J Med Microbiol</source>. (<year>2002</year>) <volume>51</volume>:<page-range>20&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1099/0022-1317-51-1-20</pub-id><pub-id pub-id-type="pmid">11803949</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramezanifard</surname><given-names>R</given-names></name><name name-style="western"><surname>Golubeva</surname><given-names>YA</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>AD</given-names></name><name name-style="western"><surname>Slauch</surname><given-names>JM</given-names></name></person-group>. <article-title>TamAB is regulated by PhoPQ and functions in outer membrane homeostasis during <italic toggle="yes">Salmonella</italic> pathogenesis</article-title>. <source>J Bacteriol</source>. (<year>2023</year>) <volume>205</volume>:<fpage>e0018323</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1128/jb.00183-23</pub-id><pub-id pub-id-type="pmid">37728604</pub-id><pub-id pub-id-type="pmcid">PMC10601761</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name><name name-style="western"><surname>Dai</surname><given-names>S</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>A tamB homolog is involved in maintenance of cell envelope integrity and stress resistance of <italic toggle="yes">Deinococcus radiodurans</italic>
</article-title>. <source>Sci Rep</source>. (<year>2017</year>) <volume>7</volume>:<fpage>45929</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1038/srep4592</pub-id><pub-id pub-id-type="pmid">28383523</pub-id><pub-id pub-id-type="pmcid">PMC5382914</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sposato</surname><given-names>D</given-names></name><name name-style="western"><surname>Mercolino</surname><given-names>J</given-names></name><name name-style="western"><surname>Torrini</surname><given-names>L</given-names></name><name name-style="western"><surname>Sperandeo</surname><given-names>P</given-names></name><name name-style="western"><surname>Lucidi</surname><given-names>M</given-names></name><name name-style="western"><surname>Alegiani</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Redundant essentiality of AsmA-like proteins in <italic toggle="yes">Pseudomonas aeruginosa</italic>
</article-title>. <source>mSphere</source>. (<year>2024</year>) <volume>9</volume>:<page-range>e00677&#8211;23</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1128/msphere.00677-23</pub-id><pub-id pub-id-type="pmcid">PMC10900882</pub-id><pub-id pub-id-type="pmid">38305166</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Douglass</surname><given-names>MV</given-names></name><name name-style="western"><surname>McLean</surname><given-names>AB</given-names></name><name name-style="western"><surname>Trent</surname><given-names>MS</given-names></name></person-group>. <article-title>Absence of YhdP, TamB, and YdbH leads to defects in glycerophospholipid transport and cell morphology in Gram-negative bacteria</article-title>. <source>PloS Genet</source>. (<year>2022</year>) <volume>18</volume>:<fpage>e1010096</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pgen.1010096</pub-id><pub-id pub-id-type="pmid">35226662</pub-id><pub-id pub-id-type="pmcid">PMC8912898</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>R</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>G</given-names></name><name name-style="western"><surname>Bottero</surname><given-names>D</given-names></name><name name-style="western"><surname>Gaillard</surname><given-names>ME</given-names></name><name name-style="western"><surname>Fingermann</surname><given-names>M</given-names></name><name name-style="western"><surname>Graieb</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Outer membrane vesicles as acellular vaccine against pertussis</article-title>. <source>Vaccine</source>. (<year>2008</year>) <volume>26</volume>:<page-range>4639&#8211;46</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.004</pub-id><pub-id pub-id-type="pmid">18640169</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name></person-group>. <article-title>Analyses of <italic toggle="yes">Brucella</italic> pathogenesis, host immunity, and vaccine targets using systems biology and bioinformatics</article-title>. <source>Front Cell Infect Microbiol</source>. (<year>2012</year>) <volume>2</volume>:<elocation-id>2</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fcimb.2012.00002</pub-id><pub-id pub-id-type="pmid">22919594</pub-id><pub-id pub-id-type="pmcid">PMC3417401</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanot Mambres</surname><given-names>D</given-names></name><name name-style="western"><surname>Machelart</surname><given-names>A</given-names></name><name name-style="western"><surname>Potemberg</surname><given-names>G</given-names></name><name name-style="western"><surname>De Trez</surname><given-names>C</given-names></name><name name-style="western"><surname>Ryffel</surname><given-names>B</given-names></name><name name-style="western"><surname>Letesson</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Identification of immune effectors essential to the control of primary and secondary intranasal infection with <italic toggle="yes">Brucella melitensis</italic> in mice</article-title>. <source>J Immunol</source>. (<year>2016</year>) <volume>196</volume>(<issue>9</issue>):<page-range>3780&#8211;93</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.4049/jimmunol.1502265</pub-id><pub-id pub-id-type="pmid">27036913</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>